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ABSTRACT
LONG- ACTING INTRADUCTAL DRUG DELIVERY SYSTEMS FOR THE
BREAST
MIBIN KURUVILLA JOSEPH
2019
Breast cancer is the second most commonly diagnosed cancer in women in the US. Ductal
carcinoma in situ (DCIS) is a premalignant lesion that has not metastasized through the
regional lymph nodes to other organs. Currently, all breast cancers including localized
breast cancers are treated with the same aggressive therapy. Localized drug delivery by
direct intraductal injections into the mammary ducts can achieve high drug concentration
at the target site. However, poor retention of drugs in the ducts limits the successful
translation of this approach to the clinic. To this end, the main goal of this dissertation is
to develop intraductal delivery systems that can sustain drug levels in the breast and reduce
the frequency of intraductal injections.
The first objective was to test the influence of particle size and formulations using
polystyrene (PS) particles (100-1000nm) and poly lactic-co-glycolic acid (PLGA)
formulations [microspheres (MS) and in-situ gel (ISG) and nanoparticles (NP)] and to test
the retention in the breast and regional lymph nodes. In vivo imaging study in rats showed
that PS 1000nm was retained in the breast for 3 days compared to PS 500 nm and PS100
nm, which were retained for 2 days. The retention t

½

PS-1000nm particles was ~4-fold

higher compared to 500nm, 100nm and free dye. PLGA MS and NP showed average
particle size of 8.66 µm and 200 respectively. In vivo fluorescence imaging study in rats
showed that PLGA ISG and MS were retained in the ducts for 4 days compared to PLGA

xv

NP and free dye, which were retained for 2 days and 4 hours respectively. The breast
retention t

½

of PLGA MS and ISG was > 4-fold higher compared to PLGA NP and free

dye. Furthermore, PLGA MS and NP were transported and retained in the regional lymph
nodes for 48 and 24 hours respectively. PLGA formulations followed a similar
biodistribution trend when tested in pig. PLGA ISG and MS were retained for 4 days and
the free dye was retained only for few hours.
The second objective was to develop intraductal formulations of tamoxifen (TMX) and
study the in vivo biodistribution of TMX and its major active metabolites [4hydroxytamoxifen (4HT) and endoxifen (EDX)] following intraductal delivery. The
optimized PLGA MS and NP showed particle sizes of 9.12 µm and 274.1 nm respectively.
In vitro release study showed that PLGA MS and ISG sustained release of TMX for > 3
weeks, while PLGA NP sustained TMX release for 2 weeks. PLGA MS and ISG T retained
TMX in the breast for 2 weeks compared to PLGA NP and free TMX, which were retained
6 and 3 days respectively. The retention t ½ of TMX was delayed by >200 hours for PLGA
MS and ISG compared to PLGA NP and free TMX. 4HT, a potent metabolite of TMX was
generated in the mammary glands with PLGA MS and ISG and the levels were maintained
above therapeutic levels for 2 weeks. No 4HT was detected in free TMX and PLGA NP
groups after 2 and 7 days respectively. At the end of the treatment period (2 weeks), the
amount of 4HT in the breast was 1.5 and 3.3-fold higher than free TMX group for PLGA
MS and PLGA ISG respectively, and the concentration of 4HT was found to be above the
therapeutic levels of 4HT in the breast. PLGA MS and ISG delayed the plasma t ½ by> 70
hours compared to free TMX. PLGA MS and ISG sustained TMX, 4HT and EDX levels
in the plasma (<5ng/ml) for 2 weeks and showed ~2 fold lower systemic exposure

xvi

compared to free TMX. The Cmax for free TMX was ~ 3- fold higher compared to PLGA
MS and ISG. PLGA MS and ISG showed significantly lower levels of TMX, 4HT and
EDX in the organs. Intraductal TMX did not show any measurable levels of TMX, EDX
and 4HT in the uterus.
The final objective of the dissertation was to develop and test intraductal formulations of
4HT in vivo. To further prolong drug release upto a month, a combination of 4HT loaded
PLGA microspheres and in situ gel (MSG) was used. In vitro release study showed that
PLGA MSG sustained 4HT release for ~1 month. MSG retained 4HT for ~1 month
compared to free 4HT, which was retained only for 1 week. EDX a metabolite of 4HT was
generated in the mammary glands treated with MSG. At day 28, EDX levels were 22-fold
higher in MSG mammary glands compared to free 4HT. Pharmacokinetic studies in rats
showed that MSG sustained 4HT and EDX levels in the plasma for 2 weeks. MSG delayed
the plasma t ½ of 4HT and EDX by >3 fold compared to free 4HT. No 4HT was detected
in the regional lymph nodes in the free 4HT group. On the other hand, MSG sustained
therapeutic levels of 4HT in the regional lymph nodes for 14 days and was undetectable at
day 28.
Taken together, the findings from this dissertation demonstrate the feasibility of developing
long acting intraductal formulations to prolong drug retention in the breast and reduce
systemic drug distribution.

1

INTRODUCTION
A. BREAST ANATOMY AND PHYSIOLOGY
The human breast is a modified cutaneous exocrine gland and the skin over the breast
connects to the underlying breast tissue through a facial layer and fibrous extensions of
Coopers ligaments.1, 2 The human breast lies on the anterior thoracic wall with its base
extending from the second to the sixth rib.3 Anatomically, the breast lies between the
between the skin and underlying organs. The skin and nipple are attached to the breast
through suspensory ligaments of cooper which are fibrous strands extending from the
dermis into the breast. However, the peripheral boundaries of the mature human breast are
not clearly defined with the exception at the deep surface where the gland overlies
pectoralis fascia. Laterally, the breast extends over portions of serratus anterior muscle,
over external oblique muscle inferiorly and over rectus sheath superiorly and medially into
the sternum. The breast tissue comprises of epithelial and parenchymal cells and the
stroma. The epithelial cells constitute 10-15% of the overall breast volume and the
remainder of the volume is filled with components of the stroma. The breast is divided into
upper inner, upper outer, lower inner and lower outer quadrant using two perpendicular
planes intersecting at the nipple or nipple centroid line.4

The human breast is composed of glandular (secretory) and adipose (fatty) tissues
supported by Cooper’s ligaments (connective tissues) (Figure1). The secretory tissue is
drained by a network of ducts that stores and transports milk during lactation5. The human
breast consists of 15-20 lobes and each lobe is further divided into 20 to 40 lobules
containing 10-100 alveoli (0.12mm in diameter)6. These lobules are composed of tubule

2

alveolar glands and it drains into a major lactiferous duct. The lactiferous ducts drain into
lactiferous sinus (2-4mm)7 which ultimately opens through orifices onto the nipple.3

3

Figure 1: Anatomy of the breast
Reproduced from https://visualsonline.cancer.gov/details.cfm?imageid=2170

4

Breast Ductal System
The human breast comprises of 15-20 mammary ductal networks but all of these ducts do
not terminate as ductal orifices at the nipple (Figure2).

8

The ductal networks can be

grouped into true mammary ducts and sebaceous glands. Studies 9, 10 have confirmed that
only 5-9 ducts terminate at the nipple and are accessible from the outside. Even though the
ductal systems are in close juxtaposition to each other, they are not connected. 8 There is
increasing evidence that breast cancer originates from a single ductal system. The sick lobe
theory describes DCIS as a lobar disease and the in situ tumor foci are localized in the
single lobe of the breast. 11 Therefore, the variabilities within each of these ducts needs to
be considered in designing appropriate treatment strategies. 8 For example, in patients with
a genetic predisposition to breast cancer (BRCA1, BRCA 2), the specific ducts express
surrogate markers before any histological changes appear. By utilizing these surrogate
markers, high risk ducts can be accessed and treated effectively.

5

Figure 2: Breast duct anatomy
Reproduced from https://visuals.nci.nih.gov/details.cfm?imageid=1810

6

Vascular and Lymphatic components in breast
Three major arteries supply blood to the breast. About 60% of the blood supply is through
the internal mammary artery arising from the internal thoracic artery. Around 30% of the
blood supply is provided by the axillary and thoracoacromial arteries, and the remainder
through the posterior intercostal arteries12.

The lymphatic system plays a prominent role in maintaining tissue fluid homeostasis. The
extravasated blood plasma and proteins are collected in the interstitial space and this forms
the lymph fluid. The lymphatic system is primarily divided into lymphatic capillaries,
collecting vessels, lymph nodes, and lymphatic trunks and ducts. Studies by Sappey13 in
the early 1870’s demonstrated that breast lymphatics are separate from the underlying torso
with the lymphatics in the subareolar plexus and a small number of large lymphatic vessels
draining into the axillary lymph nodes (Figure 3). In the superficial layer of the skin, the
lymphatics capillaries are 20-70 µm in diameter and they drain into pre-collectors that are
up to 70 - 150 µm in diameter. These capillaries drain to lymph collectors in the
subcutaneous space and are 150 - 350 µm in diameter. The lumen of lymphatic vessels are
wider and more irregular than vascular capillaries and these are composed of single layer
of endothelial cells and a discontinuous basement membrane of 10-50µm in diameter.

14

Axillary lymph nodes accounts for more than 75% of lymphatic drainage of the breast.1, 15,
16

The number of nodes in the axillary region are determined to be 20 to 30. The lymph

nodes are classified in accordance with their relationship to the pectoralis minor muscle. 3,
17

Level I lymph nodes (axillary vein, external mammary and scapular groups) are located

7

lateral to the pectoralis minor muscle. Lymph nodes found in the superficial and deep
regions of pectoralis muscle are termed as level II lymph nodes (central and interpectoral
group). Level III lymph nodes are located medial to the pectoralis minor muscle
(subclavicular group).

8

Figure 3: Breast and adjacent lymph nodes
Reproduced from https://visualsonline.cancer.gov/details.cfm?imageid=4347
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B. BREAST CANCER
Breast cancer accounts for 30% of all new cancer diagnosis in women and it is the second
most commonly diagnosed cancer amongst females in the US.

18

In 2019 alone, the

American Cancer Society estimates 268,600 new cases of invasive breast cancer and
62,930 new cases of non-invasive (in situ) breast cancer. The majority of breast cancer
originates in the epithelial cells lining the milk ducts. These malignant cells are
characterized by uncontrolled cell division of epithelial cells within the ducts (in situ
carcinoma) and if overlooked, eventually breaches the basement membrane and becomes
invasive. 19, 20

The exact cause of breast cancer is still unknown, but there are several risk factors which
contribute to its development. There is a correlation between increased risk of developing
breast cancer with an increase in age. The incidence rate of breast cancer doubles with
every 10 years of age until menopause. 21 Other factors include limited blood supply to the
ducts,

22

age at menarche and menopause, age at first pregnancy, and family history.

21

Women with mutations in two genes, BRCA1 and BRCA2 are associated with increased
risk of developing breast cancer. It is found that about 5-10% of breast cancer cases are
due to this mutation and there is an 80% chance that these women will develop breast
cancer during their lifetime. 21, 23 Cells that lack BRCA1 and BRCA 2 have deficiency in
repairing the double strand breaks of DNA. The resulting genomic instability contributes
to the underlying mechanism to breast cancer.

24

Breast cancer incidence rates are

increasing in countries with historically higher incidence rates such as in Europe, as well
as in regions with lower incidence rates which includes some countries in Latin America,

10

Asia and Africa.

25

Some of the factors that accounts for this rising trend are altered

reproductive patterns such as age at first pregnancy, breast feeding duration, number of
childbirths and lifestyle changes. 26, 27,28

The majority of the breast cancers are localized and there is a lack of clear understanding
of tumors that will eventually become invasive breast cancer.

29

Lymphatic system also

plays a key role in cancer metastasis and breast cancer mortalities are primarily due to
metastasis to other organs through the regional lymph nodes. The is pathological
examination of lymph nodes is used for determining the stage of the cancer and metastasis.
30

Generally, lymphatic drainage of the breast occurs to the adjacent lymph nodes and not

to lymph nodes on the contralateral breast. Hence, there is minimal chance of cancer
metastasis to the contralateral nodes. 17 However, extensive blockage of lymphatic vessels
results in subcutaneous lymphatic permeation to occur on the opposite breast.

Types of Breast Cancer
Breast cancer can be classified based on the stage of cancer 31(Table 1), epithelial origin
and molecular subtypes.
Based on the epithelial origin32 breast cancers can be grouped into:
I. DCIS (Ductal carcinoma in situ) is designated as Stage 0 in the AICC (American
Joint Commission on Cancer) staging of breast cancer. DCIS is the abnormal
proliferation of epithelial cells lining the mammary ducts (Figure 4). In situ refers
to the fact that the malignant cells have not breached the basement membrane out
into the stroma in the breast.
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II. IDC (Invasive ductal carcinoma) remains the most prevalent type of invasive breast
cancer and accounts for 70-80% of all cases (Figure 5). In IDC, the malignant cells
spread throughout the breast tissue, blood vessels and the lymphatic system and
metastasize to regional lymph nodes, and in advanced cases to the rest of the body.
Around 75% of IDC are ER (estrogen receptor) and PR (progesterone receptor)
positive and 15-20% expresses growth factor receptor HER2 (human epidermal
growth factor receptor 2).
III. ILC (infiltrating lobular carcinoma) is the second most common IDC. It is
generally ER positive and found to occur more frequently in older women. ILC is
characterized by a lack of cellular adhesion due to alterations in E-cadherin, a
protein that aids in cell adhesion that is deleted or mutated.32 The lack of cellular
adhesion gives rise to a single pattern of cells microscopically which is a
distinguishing feature of ILC.

12

Table 1: Breast cancer classification based on stage of the cancer
Stage

Classification

Stage 0

In situ

Stage 1

Early stage – Invasive

Stage II

Early stage – Invasive

Stage III

Locally advanced

Stage IV

Metastatic

13

Figure 4: Ductal carcinoma in situ
Reproduced from https://visualsonline.cancer.gov/details.cfm?imageid=4353
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Figure 5: Invasive breast cancer
Reproduced from https://commons.wikimedia.org/wiki/File:Invasive_breast_cancer.jpg
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Molecular subtypes of breast cancer
Breast cancer is also classified based on immunohistochemical expression of ER (estrogen
receptor) PR (progesterone receptor), HER2 (human epidermal growth factor 2 receptor)
and Ki67. 33, 34 The four main types are:
1.

Luminal A (ER+ or PR+, HER-2-)

2.

Luminal B (ER+ or PR+, HER-2+)

3.

HER2 (ER- or PR-, HER-2+)

4.

Triple Negative (ER- or PR-, HER-2-)

1. Luminal A breast cancer
Based on the molecular profile, majority of infiltrating lobular carcinomas belong to
Luminal A subtype. This accounts for 50-60% of all cases of breast cancer35. The
expression of estrogen receptors is similar between Luminal A breast cancers has low
expression of cell cycle related genes (eg: MK167 and AURKA), and higher expression of
luminal related proteins such as progesterone receptor and FOX 1. Luminal A tumor
subtype also show a lower number of mutations across the genome. The patients with this
type of cancer have better prognosis compared to Luminal B subtypes, but is associated
higher incidence of bone metastasis in patients with tumor relapse. 35 The treatment options
include aromatase inhibitors, selective estrogen receptor modulators and selective
regulators like tamoxifen and fulvestrant respectively. 36, 37

16

2.

Luminal B breast cancer

This subtype represents 10-20% of all breast cancer cases. Luminal B subtype is more
aggressive and has poor prognosis

33

compared to luminal A type. The main factor that

distinguishes this subtype from luminal A type is the increased expression of proliferation
genes such as MK167 and cyclin B1, and expression of HER2 and EGFR. The luminal B
subtype has tumors with ER+/HER-2+ with high Ki67 expression. The treatment is
challenging because of the poor prognosis. The luminal B type responds better to
neoadjuvant chemotherapy achieving complete response in 17% of cases. 33, 37 Studies are
underway to determine the mechanisms of metastasis vis-a-vis effective treatment
approaches for this subtype. 37

3.

HER-2 positive breast cancer

The human epidermal growth factor receptor 2 (HER-2) gene encodes a transmembrane
tyrosine kinase receptor protein that is a member of epidermal growth factor receptor
(EGFR).38 An increased expression of HER-2 gene/protein expression constitutes 10-34%
of all invasive breast cancers.39 This tumor subtype is characterized by higher expression
of HER-2 related and proliferation related genes and proteins. At the DNA level, this shows
the highest number of mutations across the genome. This type of tumor constitutes 15-20
% of all cases of breast cancer cases and has a poor prognosis.39 However in the last decade
anti-HER2 therapy has significantly improved the survival of patients with HER2 positive
breast cancer.40

4.

Triple negative/basal-like breast cancer

17

The basal like tumors represents 10-20% of all breast cancers. The term basal like is used
because of the similarities in the expression of genes (CK5 and CK 17, EGFR. CD 44 etc.)
in normal myoepithelial cells and luminal epithelium33 (CK8/18, Kit etc.), but at
significantly lower levels than luminal subtypes. These tumors show a high response rate
to chemotherapy; however, have a higher rate of relapse within the first three years and a
worse prognosis than luminal types. One of the key features of this subtype is the absence
of ER, PGR and HER-2. These tumor subtypes tend to be infiltrating carcinomas with
aggressive metastasis visceral organs, mainly lungs, CNS and lymph nodes. 36 The standard
systemic treatment for triple negative cancer follows the same principle as other types of
breast cancer.

41

One of the most promising therapies to treat these tumors is poly-

ADPribose-polymerase-1 (PARP-1) inhibitors, which is associated with a higher response
rate and clinical benefit. 42 The advance of multiomics have led to the discovery of targeted
therapies which can be particularly beneficial for this subtype.

C.THERAPEUTIC APPROACHES FOR BREAST CANCER
Breast cancer treatment regimens depends upon several factors like the extent of tumor
lymph node metastasis, grade of the tumor, hormone receptor status and HER2
overexpression, age and menopausal status of the patient. The most common treatment
modalities currently used are described below.
1.

Surgery

2.

Radiotherapy

3.

Chemotherapy

4.

Hormone Therapy

18

5.

1.

Targeted Therapy

Surgery

Currently most of the early stage tumors are removed by surgical approaches. 43 However,
the major drawback is that the chance of tumor relapse is unpredictable. Adjuvant
chemotherapy is recommended along with surgery, which results in unwanted side effects.
44

In case of patients with larger tumor size and high nodal involvement at diagnosis,

neoadjuvant therapy is recommended with the goal being to shrink the tumor to aid surgery.
Earlier, the standard treatment for breast cancer was limited to mastectomy, which is the
complete removal of breast tissue along with the underlying muscle tissue and the
associated lymph nodes.

45

This procedure significantly impairs the quality of life of

patients and several studies 46 show increased risk of depression and body image issues in
these patients. However, improvements in mammographic screening techniques lead to
early diagnosis and a reduction in mastectomy.

47

As a result, local resection of the tumor

followed by radiotherapy with chemotherapy is favored for patients diagnosed with breast
cancer. 48

Breast conservation surgery (Lumpectomy) is an established procedure for women
diagnosed with early stage breast cancer. It involves the surgical resection of tumor,
axillary node dissection followed by radiotherapy of the affected breast.49 Almost two
thirds of patients are eligible for breast conservation surgery, with an average presentation
of tumor size at less than 2 cm. However lumpectomy does not completely eliminate the
chances of tumor relapse in the conserved breast. The major factors that determine the local
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recurrence within the conserved breast are the margin status and an extensive in situ
component. Other factors include age (< 35 years) and nodal status, large tumor size (>2
cm), and higher histological grade at the time of surgery.

The choice of adjuvant chemotherapy depends on several factors ranging from the extent
of spread of tumor locally or to the axillary lymph nodes. Depending upon the stage of
cancer, sentinel lymph node technique allows for the removal of axillary lymph nodes
bypassing the need for axillary curettage if these nodes are not invaded.50 Axillary lymph
node dissection is associated with edema, numbness, pain and decreased mobility of the
affected arm. As a general procedure in breast conservation therapy, radiation therapy
accompanies the treatment and the affected breast is irradiated with additional dose of
radiation to the tumor excision region and to the lymph node regions.

2.

Radiotherapy

Different types of radiation therapies such as external beam radiation therapy,
brachytherapy and systemic radioisotope therapy and fractionation regimens are employed
in many types of cancer including breast cancer. 51 Radiotherapy is also used to reduce the
size of the tumor before lumpectomy and is also as a way to reduce the treatment burden
to the patient undergoing chemotherapy.

52

With technological advancements, image-

guided treatment devices enabled more precise delivery of high intensity beams of
radiation to tumor site with decreased damage to healthy surrounding tissue. However, the
overall benefit from radiotherapy is unpredictable as some of the tumor cells resist radiation
damage giving rise to recurrent tumors for which there are limited treatment options
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available.53 Also, radiation therapy is expensive and time consuming and hence shorter
treatment options are preferred by patients.54

3.

Chemotherapy

The potential for the development of chemotherapeutic drugs dates back to the First World
War when soldiers who underwent treatment after exposure to sulfur mustard gas
developed lymphoid aplasia. Later, nitrogen mustards became the first chemical agents to
be tested in clinic and showed remarkable results in lymphoma patients.55 Most of
chemotherapy drugs reduce the rate of cell growth either by interacting with the DNA or
by interfering with cell division. 56
These drugs lack the ability to distinguish between normal and cancer cells and this nonspecificity result in serious side effects. They are used either as single agents or in
combination to reduce the chances of cancer resistance towards a single agent. The drugs
and drug combinations approved by USFDA to treat breast cancer are listed in Tables 2
and 3. If the cancer is diagnosed at later stages, the goal of chemotherapy is palliative and
treat the symptoms to improve quality of life.55 The common prognostic indicators for
breast cancer include the size of tumor, grade, lymph node evasion and age. The presence
of hormone receptors (estrogens and progesterone), overexpression of epithelial growth
factor receptor 2 (HER2) and Ki67 index which quantifies the cellular proliferation levels
have been included as prognostic indicators in the recent years.52 Administration of
chemotherapy after surgery has improved the rates of disease free and overall survival rates
is contingent upon the above mentioned prognostic markers.

57, 58

Anthracyclines and

taxanes (paclitaxel and docetaxel) are considered to be most beneficial for adjuvant
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chemotherapy. A randomized study showed improved survival upon administration of four
cycles of doxorubicin/cyclophosphamide (AC) followed by four cycles of paclitaxel.59 In
a larger randomized trial, patients were administered four cycles of AC followed by
paclitaxel once in three weeks or weekly, docetaxel once in three weeks or weekly
docetaxel. Improved survival rates were observed with four cycles of AC followed by a
single dose of paclitaxel every week for 12 weeks.
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Table 2: USFDA Approved chemotherapeutic agents for breast cancer
Drug

Route of Administration

Paclitaxel Albumin- stabilized

IV

Nanoparticle Formulation
Pamidronate Disodium

IV

Capecitabin

Tablet

Cyclophosphamide

IV, tablet, capsule

Docetaxel

IV

Doxorubicin Hydrochloride

IV, liposomal

Epirubicin Hydrochloride

IV

Eribulin Mesylate

IV

Everolimus

Tablet

Exemestane

Tablet

5-FU(Flurouracil)

IV

Gemcitabine Hydrochloride

IV

Methotrexate

IV, Tablet

Paclitaxel

IV

Thiotepa

IV

Vinblastine Sulfate

IV

IV – Intravenous, 5FU- 5 Fluorouracil
Source: National Cancer institute (https://www.cancer.gov/about-cancer/treatment/drugs/breast)
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Table 3: USFDA approved combination chemotherapy for breast cancer treatment
Code
AC

Drugs used in combination
Doxorubicin Hydrochloride, Cyclophosphamide

AC-T

Doxorubicin Hydrochloride, Cyclophosphamide, Paclitaxel

CAF

Cyclophosphamide, Doxorubicin Hydrochloride, Fluorouracil

CMF

Cyclophosphamide, Methotrexate, Fluorouracil

FEC

Fluorouracil, Epirubicin Hydrochloride, Cyclophosphamide

TAC

Docetaxel, Doxorubicin Hydrochloride, Cyclophosphamide

Source: National Cancer institute (https://www.cancer.gov/about-cancer/treatment/drugs/breast)
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Limitations of chemotherapy
The process governing cell division (mitosis and apoptosis) are common to tumor cells and
normal cells and chemotherapy affects both cell populations. The goal of treatment is to
attain sufficient tumor cell killing while limiting toxicity towards normal cells. However,
the therapeutic index for most conventional chemotherapy drugs is close to one and toxicity
to the normal cells is dose limiting.

56

During the treatment period, the rapidly dividing

cells of the GI tract, hair follicles, bone marrow and gonads are predominantly affected by
these drugs. The common side effects include hair loss, nausea and vomiting,
myelosuppression and reduced fertility.

56

Also, majority of these drugs can cause

teratogenicity effects and hence harmful to the fetus. Long term effects of chemotherapy
include the potential for development of cardiomyopathy caused by doxorubicin and
pulmonary fibrosis due to treatment with bleomycin. 60 Some of the common side effects
of chemotherapy associated with chemotherapy agents are listed in table 4.
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Table 4: Common adverse effects of cytotoxic chemotherapy 55
Tissue

Manifestations

Agents likely to cause toxicity

Reticuloendothelial

Neutropenia

Alkylating agents, anthracyclines,

Anaemia

taxanes, Topoisomerase inhibitors

Thrombocytopenia
Gastrointestinal

Diarrhoea

Antifolates, fluoropyrimidines

Oral mucositis

Various

Nausea and vomiting
Neurological

Peripheral sensory

Vinca alkaloids, taxanes

neuropathy

Cisplatin, oxaliplatin

Ototoxicity
Renal

Acute renal failure

Cisplatin

Hepatic

Transaminitis

Raltitrexed

Cardiac

Acute or chronic

Anthracyclines

cardiomyopathy

Fluoropyrimidines

Cardiac ischaemic events
Respiratory

Pulmonary fibrosis

Bleomycin

Bladder

Haemorrhagic cystitis

Cyclophosphamide
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Others

Hand-foot syndrome

5FU infusion, capecitabine

Vesicant

Doxorubicin, vincristine

Anaphylaxis

Taxanes

Alopecia, fatigue, lethargy

Combination chemotherapy containing

Subfertility/infertility

alkylating agents

Increased risk of second
malignancy
Reproduced from Corrie, P.G., 2008. Cytotoxic chemotherapy: clinical
aspects. Medicine, 36(1), pp.24-28.
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4.

Endocrine/Hormone Therapy

Hormone receptor positive (estrogen and progesterone) breast cancer constitutes 65-75%
of all breast cancers.

61

In this subtype, the tumor cells are largely dependent on female

hormones for their growth and survival. The serum concentrations of the major hormones
estrogen and progesterone are regulated through hypothalamic-pituitary-gonadal axis. In
pre-menopausal women, estradiol is synthesized by ovaries whereas in post-menopausal
women, estradiol is produced from adrenal androgens in the peripheral tissues mainly
adipose tissues. 62

The two main classes of drugs used for endocrine therapy are i) selective estrogen receptor
modulators (SERM’s) and ii) aromatase inhibitors (AI’s). SERM’s binds competitively to
the estrogen receptors and interfere with the DNA synthesis and eventually inhibit G0 to
G1 cell cycle progression. 63 AI’s inhibit the enzyme aromatase which converts circulating
testosterone and androstenedione to estradiol and estrone respectively by aromatization. 64
Hence AI’s is proven to be beneficial in post-menopausal women, where the primary
source of estrogen is depleted. The most commonly reported side effects of hormone
therapy are hot flashes, weakness and tendency towards weight gain and depression.

52.

Although rare, but serious, these agents also cause thrombo-embolic events and
endometrial cancer. 52 There are also reports of reduced bone density resulting in increased
fracture rate and an increase in the coronary artery events with these agents. 65 The USFDA
approved endocrine therapy agents to treat breast cancer listed in Table 5.

1. SERM’s
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Estrogen is a steroid hormone that plays a major role in growth and function of breast,
uterus and ovaries. It also plays a key role in maintaining bone density and lowering the
cholesterol levels in the body. In case of ER+ cancers, it stimulates the growth of cancer
cells in the breast and uterus. Estrogen mediates its action through estrogen binding
receptors (ERα and Erβ)

that function as transcription factors which regulates the

expression of estrogen responsive genes61, 66.

SERM’s act as agonist to maintain the cholesterol levels and bone density, and has
antagonistic effects in the breast tissue67. Tamoxifen is a widely used anticancer drug in
post-menopausal women with axillary lymph node positive and in pre and post-menopausal
women with lymph node negative ER+ cancers. It has also been used as a chemopreventive
agent to reduce the risk of breast cancer in high risk and in pre and post-menopausal women
with breast cancer68.

2. Aromatase inhibitors
Aromatase inhibitors are another class of drugs that are of significance in adjuvant therapy
for breast cancer. In post-menopausal women in which the ovaries are dysfunctional,
estrogen is produced peripherally by the conversion of androgens by the enzyme
aromatase69, 70. Aromatase belongs to the family of CYP450 enzymes and it catalyzes the
final step of estrogen biosynthesis. Three of the approved AI’s (Table 5) for treating breast
cancers show better activity than tamoxifen, however the long-term safety of these agents
is still under investigation. AI’s are considered to be standard treatment for postmenopausal
women. The American Society of Clinical Oncology states that the adjuvant chemotherapy
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should include an aromatase inhibitor as an initial therapy or after tamoxifen therapy for 25 years71.
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Table 5: USFDA approved hormone therapy drugs for breast cancer

Drug

Target

Tamoxifen

SERM

Tamoxifen Citrate

SERM

Raloxifene

SERM

Toremefine

SERM

Fulvestrant

EA

Anastrozole

AI

Exemestane

AI

Letrozole

AI

AI – Aromatase inhibitor, SERM-Selective estrogen receptor modulator, EA estrogen
antagonist
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5.

Targeted therapy

A greater understanding of the biological factors that play a role in breast cancer has
identified new molecular targets. Breast cancer cells sustain and proliferate by several
growth factor receptors driven signaling pathways. Of note are the epidermal growth factor
receptor (EGFR) family of tyrosine kinase receptors which includes four different types:
EGFR (ErbB-1), ErbB-2 (HER2), ErbB-3 and ErbB-4.72 Each of these receptors possess
a ligand binding domain in the extracellular space, a transmembrane domain and a tyrosine
kinase containing domain in the cytoplasm inside the cell. Upon the binding of peptide
growth factors to these receptors dimerizes, which in turn activates kinase enzyme which
then phosphorylates tyrosine residues73. Some of the known targets for tyrosine kinase
inhibitors (TKI’s) include HER1, HER2, HER3, Insulin growth factor receptor (IGFR),
hepatocyte growth factor receptor (C-MET), fibroblast growth factor receptor (FGF) and
intracellular targets which includes Phosphoinositide 3-kinase (PI3K), protein kinase B
(PKB/AKT), mammalian target of rapamycin (mTOR), extracellular signal-regulated
kinase (ERK).74

Human epidermal receptor (HER) family of receptors is classified into HER1, HER2,
HER3 and HER4. Amongst these HER2 amplification is present in 10-34% of breast
cancers 39 and is linked to poor prognosis. 75 In one of the trials, trastuzumab, a monoclonal
antibody directed against HER 2-receptor showed early survival benefit in patients with
HER 2 positive early stage breast cancer. In this study, trastuzumab was administered
concurrently with anthracyclines (AC) based chemotherapy (AC followed by
paclitaxel/trastuzumab) followed by 52 weeks of trastuzumab. Lapatinib is another small
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molecule tyrosine kinase inhibitor directed against epidermal growth factor and HER2. A
combination of Lapatinib and capecitabine improved the survival rates in patients with
metastatic breast cancer.

76

Pertuzumab is another monoclonal antibody that binds to a

different domain of HER 2 protein. A combination of trastuzumab and pertuzumab showed
synergistic action in preclinical studies. 77 Overexpression of insulin-like growth factor 1
receptor (IGF-IR) is associated with poor prognosis as well as resistant towards several
drugs. 78 Activation of signaling pathways triggered by binding of ligands to these growth
factor receptors are well characterized in breast cancer cell lines. Of significance are
mitogen-activated protein kinase (MAPK) and PI3K/Akt/mTOR pathways and clinical
trials are underway to test several inhibitor molecules targeting various aspects of these
pathways. 78 (Table 6)
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Table 6: Biological targeted therapy in development for the treatment of breast cancer79
Agent

Target

Current Phase of
Clinical Development

Pertuzumab

HER2

III

TDM1

HER2

III

Erlotinib

EGFR

II

Afatinib

EGFR, HER2

III

Neratinib

EGFR, HER2

III

Aflibercept

VEGF

II

Sunitinib

PDGFR, VEGFR-1, VEGFR-2,c-KIT,

III

FLT3
Sorafenib

PDGFR, VEGFR-2, RAF

II

Axitinib

PDGFR, all VEGFR, c-KIT

II

Vandetanib

VEGFR, EGFR

II

Pazopanib

PDGFR, all VEGFR, c-KIT

Temsirolimus

mTOR

II

Everolimus

mTOR

III

Ridaforolimus

mTOR

II

Cixutumumab

IGF-1R

II

AMG 479

IGF-1R

II

Dasatinib

Src

II

Bortezomib

Proteasome

II

III
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Tanespimycin

Hsp90

II

Rataspimycin

Hsp90

II

Vorinostat

HDAC

II

Iniparib

PARP1

III

Olaparib

PARP1

II
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D. LOCALIZED CHEMOTHERAPY
The chemotherapy drugs approved for breast cancer are associated with short-term and
long-term side effects. With the goal to minimize these side effects, localized delivery
approaches have been explored. These approaches include transdermal, transpapillary
(topical application on the nipple) and intraductal drug delivery.

1.

Transdermal delivery

As the largest organ in the human body, skin provides convenient site for drug
administration. However, the skin has naturally evolved to protect the entry of foreign
molecules and to minimize the water loss from the body. The human skin is made up of
epidermis, dermis and subcutaneous tissue (Figure 6). The skin’s barrier function is entirely
accomplished by the outermost layer of the epidermis of the skin – stratum corneum (1015 µm thick). This layer is composed of compressed keratin filled corneocytes (terminally
differentiated keratinocytes) embedded in a lipid rich matrix.80-83 The lipids in SC are
different from phospholipids in cell membranes in the following aspects. 83
a) Continuous phase and diffusion path from the surface to the base of the stratum
corneum
b) Unique in its composition which consists of ceramides, free fatty acids and
cholesterol and absence of phospholipids
c) Exists as multilamellar sheets
d) Presence of saturated long chain hydrocarbons which facilitates highly ordered
configuration
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Figure 6: Skin structure.
Image reproduced from https://visualsonline.cancer.gov/details.cfm?imageid=4604
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Due to the presence of this formidable barrier, an ideal molecule for transdermal delivery
should possess the following properties to cross the skin. These include molecular weight
< 500 Da, Log P 1-3, aqueous solubility >1 mg/ml, dose < 1 mg per day and a low melting
point81. Candidates that are currently approved have molecular weight of only up to a few
hundred Daltons, partition coefficient predominantly favors lipids and the dose
requirements of 1 mg or less per day.84 There are three major routes of drug absorption
pathways after transdermal delivery.85, 86
i)

Transcellular route: The drug traverses through alternating layers of cells and
extracellular matrix. This involves a series of partitioning between alternating
hydrophobic and hydrophilic domains. Lipophilic molecules tend to follow this
route of drug permeations.

ii)

Paracellular route: In this the drug molecules takes a tortuous path within the
extracellular matrix without traversing through the cells. Hydrophilic molecules
tend to favor this route of permeation.

iii)

Transappendgeal route: The drug molecules permeate through the hair follicles
or sweat ducts and are also known as shunt pathway or transfollicular pathway.

The simplest approach to enhance permeation involves formulation approaches ranging
from modifications of partition coefficient (Ksc/veh) 83 and using different vehicles as well
as using supersaturated drug solutions87 to other formulations like microemulsion

88

and

liposomal systems.89 The most extensively researched enhancement method involves
chemical enhancers that can reversibly compromise the skin barrier to allow molecules to
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pass through the membrane. These includes alcohols, fatty acids, sulfoxides, esters,
terpenes, surfactants and phospholipids to mention a few.90
Due to its unique features of skin in the breast, the human breast has been explored for
transdermal delivery.

91-94

These features include embryological origin of the breast as a

skin appendage, lymphatic circulation and presence of fatty envelope (subcutaneous and
retromammary). 95 Topical application of 4-hydroxytamoxifen resulted in higher local drug
levels and minimal systemic exposure.91 Topical gel formulations of 4-hydroxy tamoxifen
and endoxifen to the mammary glands achieved higher drug levels in the mammary glands.
But, this approach resulted in systemic exposure of the drug, as the levels were similar for
topical gel and systemically treated groups.95 In a preclinical study, topical toremifene was
able to achieve higher breast concentrations in baboon model with undetectable serum
concentrations.96 In another study, transdermal delivery of SERM’s were investigated for
its permeation across porcine skin. Results showed significant enhancement in the
permeation of SERM’s via breast skin.97 However, further studies are required to validate
the drug localization in the breast ducts and its retention in the ducts.

2.

Transpapillary delivery

Transpapillary delivery involves drug delivery through the ductal openings at the nipple.
98, 99

Despite being a disease of the ducts, delivery of drugs through the mammary papillae has
not received considerable attention until recently. For the very first time Heard et al

98

demonstrated the transpapillary delivery of tamoxifen and two other test compounds in
vitro. In another study99, the effect of lipophilicity of molecules via transpapillary route
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was investigated. The study found that hydrophilic molecules are better candidates for drug
delivery via this route. In a follow up study100, delivery of macromolecules ranging from 5
to 67 KDa was demonstrated in vitro. The study showed a decrease in the permeability of
macromolecules with increasing molecular weight and higher permeation achieved
through the nipple compared to breast skin. In an attempt to enhance the permeation of
hydrophobic molecules through this route, influence of hydro alcoholic vehicles on the
permeation of 4-hydroxtamoxifen was investigated. The study showed that an increase in
the alcohol concentration resulted in increased permeation of 4-hydroxytamoxifen to the
mammary papilla serving as a depot releasing the drug after treatment.101 In a more recent
study, the transport pathway through this route was characterized using model dyes. The
results showed that hydrophilic molecule was mainly transported through transepidermal
pathway whereas lipophilic via transductal route. In another study102 by the same group,
nanoemulsions with higher water content enhanced the penetration of hydrophobic dye into
the nipple. In a follow up study103, the same group used liposomes to skew the permeation
through the ducts. This route has been explored for the therapeutic potential of a natural
chemopreventive agent α-santalol. Results showed that transdermal delivery of the
compound through the breast and mammary papilla enhanced local drug concentrations
with undetectable levels in the plasma. Also, transdermal delivery of α-santalol reduced
the tumor incidence and tumor multiplicity in rats. 104

Despite the advantages of this route, further studies are needed to validate the amount drugs
reaching the mammary ducts where 95% of breast cancers originate and also the
localization of the penetrated drug molecules within the ductal network. Retention of drug
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molecules in the mammary ducts is poor and despite an increased permeation through the
nipple, the retention of these compounds in the mammary gland needs to be further
investigated. Another limiting factor is the inability of this approach to distinguish the
diseased duct vs healthy duct. Moreover, the limited surface area of the nipple restricts the
delivery of only potent compounds for drug absorption via this route.

3.

Intraductal Delivery

Intraductal delivery involves delivering therapeutic agents to the breast ducts by
cannulating the diseased duct through the nipple. This allows for the delivery of
therapeutic agents directly to the tumor forming ducts thereby enhancing drug levels at
the tumor site.
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This approach has precedence and the first study dates back to as early as 1842 by Ashley
Cooper.105 In this study, Cooper intraductally injected colored waxes into the breast and
described the human breast as separate lobes comprising of a central duct, its peripheral
branches and associated glandular tissues. Subsequently this route has been explored for
therapeutic and preventive options for breast cancer (Table 7). Earlier studies have also
investigated the potential for mammary tumorigenesis in rat models after intraductal
delivery of activated Raf.106 Results showed efficient expression of the protein and tumor
induction in a small fraction of mammary epithelial cells in situ. Another study explored
the delivery of adenoviral vectors carrying thymidine kinase gene107, followed by ip
administration of ganciclovir. Results showed efficient transduction and ablation of
proliferating cells (>90%) but the tumor incidence in treatment group was found to be
higher compared to control. The first chemopreventive study was performed by Yasuo
Kamiyama108 and colleagues using a microtubule inhibitor, paclitaxel. Paclitaxel
significantly reduced tumor burden at the end of 36 weeks in N-Methyl-N-nitrosourea
(MNU) induced mouse model compared to ip injection. Moreover, intraductal paclitaxel
did not produce any toxic side effects such as weight loss or local duct damage. Also, the
cytotoxic effects were confined only to the developed tumor.108

In a study by Sukumar et al109, 4-Hydroxytamoxifen and PEGylated liposomal doxorubicin
(PLD) were investigated for chemoprevention and therapy in MNU-induced murine
models. Intraductal 4HT showed chemopreventive effects comparable to subcutaneously
administered tamoxifen group. However, no metabolites were reported to be produced in
the mammary glands. Intraductal PLD once a week for 2 weeks resulted in complete
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regression of tumors and the animals remained tumor free for 3 months. Pharmacokinetic
studies showed that intraductal doxorubicin rapidly diffused out of the ducts into systemic
circulation and peak plasma levels in was observed at 4 hours. However, PLD delayed the
Tmax of doxorubicin to 24 hours due to delayed release of doxorubicin from liposomal
formulations. In a clinical study conducted subsequently

110

, the same group tested the

feasibility and safety of PLD in females awaiting mastectomy. Intraductal delivery resulted
in only a mild breast discomfort during drug delivery and mastectomy specimens showed
a wide distribution of formulations in the duct reaching the terminal lobular units. This was
one of the first clinical study which established the feasibility of intraductal delivery in
human subjects. In the same study, other anticancer drugs (carboplatin, nanoparticle
albumin-bound paclitaxel and methotrexate) along with 5-FU were tested for efficacy in
MNU induced mammary tumors in rat. Amongst the agents tested, intraductal 5-FU
showed significant protective effects against development of lesions as well as complete
regression of established tumors. In this study, it is important to note that 5-FU showed
efficacy in treated and untreated mammary glands bearing tumor indicating systemic
exposure from the intraductally treated mammary glands.

Sinko et al tested the influence of polymer molecular weight and architecture on intraductal
retention. The breast t ½ of fluorescein disodium was increased up to 21.5 ± 2.7 hrs when
conjugated with 40 KDa PEG compared to free dye which exhibited a t

½

of only 14.5 ±

1.4 minutes. In a subsequent study22 by the same group, doxorubicin conjugated to higher
molecular weight PEG carriers enhanced ductal retention (10-12 hours). Nanoemulsions
In a more recent study, nanoemulsions containing ceramide was retained in the mammary
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glands for 6 days.

111

The improved retention of ceramide in the mammary glands was

attributed to the increased lipophilicity of ceramide (Log P > 6) suggesting improved
retention of hydrophobic compounds in the mammary glands. Despite advancements in the
field, the major challenge of poor intraductal retention remains to be further investigated.
Additional studies are required to understand the formulation factors that influence the
retention of drugs in the ducts for designing optimal formulations for intraductal delivery.
This includes devising a formulation strategy to minimize the frequency of intraductal
injections. To this end, the major goal of this study is to develop long-acting intraductal
delivery systems which will sustain drug levels in the breast and reduce the frequency of
injections.
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Table 7: Summary of intraductal delivery studies

Preclinical/
Drug

Year

Clinical

Findings
Intraductal paclitaxel significantly reduced the tumor burden. No toxic

Paclitaxel

2005

Rats

effects on normal cells108
4-HT and PLD caused regression of established tumors and prevented

4-HT, PLD

2006

rats, mice

tumorogenesis. No long term changes in histopathology of mammary
glands109

5-FU, Carboplatin,
paclitaxel nanoparticles,

5-FU showed greatest antitumor effects amongst 5 agents in rats. Carboplatin
2011

rats, humans

PLD, methotrexate

showed beneficial effects in early and established tumors in rats. PLD well
tolerated in humans with only mild discomfort110.
Alteration in structure of mammary glands and tumor formation upon long

PLD

2012

Mice

term studies (80 weeks)112
Able to lower the administered dose by 20 fold

Curcumin

2012

Rats
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Significantly lowered mammary tumor incidence with significant reduction
in nuclear factor κβ113
Intraductal retention increased with increase in molecular weight, retention
PEG

2012

Rats

decreased with increase in branching for same molecular weight,
nanocarriers delayed the tmax
PLD showed mild erythema and swelling of breast at 50mg dose, carboplatin

PLD, Carboplatin

2014

Humans

showed mild nausea and vomiting at 300mg dose, both drugs rapidly
diffused out of ducts to systemic circulation114

siRNA

2014

Mice

Suppressed cell proliferation and reduced mammary tumor incidence by
75%115
Therapeutic efficacy of radioimmunoconjugate reduced the dose from 120

225Ac-trastuzumab

2016

Mice

nCi per mouse (IV) to 30-120 nCi per mouse (ID), No renal toxicity or loss
of body weight upon intraductal administration116
Ablation of mammary epithelial cells, delayed tumor onset from 153 to 239

Cisplatin combined with
PARP1 inhibitor

2017

Mice

days, long term toxicity studies demonstrated tumor formation by 6.3% due
to systemic exposure to cisplatin117
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Ceramide

Prolonged drug localization by more than 120 hours, no histological changes

nanoemulsions

2018

Rats

in the mammary glands111

PEG-Doxorubicin

2018

Rats

Intraductal retention is influenced by architecture of nanocarriers22

Piplartine

2019

nanoemulsions
Fulvestrant

2019

Charge of bio adhesive polymer does not have an impact on intraductal
Rats

retention, mammary retention upto 120 days with no tissue damage118

Rats

Intraductal fulvestrant showed comparable or better therapeutic efficacy in
two preclinical animal models through degradation of ERα, inhibition of
angiogenesis, ↓c-Myc and Cyclin D1, ↑ERβ 119

4-HT- 4-hydroxytamoxifen, PLD – Pegylated liposomal doxorubicin, 5-FU – 5- Fluorouracil, PEG – Polyethylene glycol, Ac
– Actinium, PARP - Poly ADP ribose polymerase, ER is estrogen receptor

47

E. SCOPE AND GOAL OF THIS STUDY
About 1 in 8 U.S. women will develop invasive breast cancer over the course of her
lifetime. Ductal carcinoma in situ (DCIS) is pre-invasive breast cancer and accounts for
20% cases of all diagnosed case of breast cancer.

120

DCIS is characterized by the

proliferation of epithelial cells of milk ducts and terminal lobular units that have not
breached the basement membrane and become invasive. 120 Although the precise pathways
of tumor incidence and progression are poorly understood, majority of invasive carcinomas
arise from DCIS. The standard treatment for DCIS is normally a combination of breast
conservation surgery followed by radiotherapy with adjuvant chemotherapy depending on
the stage of cancer. 31

Systemic chemotherapy results in significant short-term and long-term side effects. 55, 121,
122

Therefore, there is a need to develop localized delivery systems that can enhance drug

concentration in the breast and minimize adverse effects. DCIS being confined to the
breast, intraductal delivery enhanced drug concentration in the breast and minimized
systemic exposure.

110, 123

Moreover, this approach showed improved efficacy in pre-

clinical and clinical studies. 114 108, 110, 119 However, the major drawback of this approach is
the rapid diffusion of drugs into systemic circulation, warranting repeated intraductal
injections to sustain drug levels in the ducts. 22, 124 To this end, the main goal of the present
study is to develop long acting intraductal delivery systems to minimize the frequency of
injections and to sustain drug levels in the breast.
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Recent studies

22, 111

have used polymer drug conjugates and emulsions to sustain drug

retention in the ducts. However, the critical determinants of developing long- acting
delivery systems including the formulation matrix and particle size and its influence on
intraductal retention is yet to be studied. Poly (lactic-co-glycolic acid) [PLGA] is a widely
used polymer for developing sustained release formulations.

125-129

Several PLGA long-

acting formulations including microspheres and in situ gel systems are used for wide
ranging applications. 125, 130, 131 However, these are yet to be explored for drug delivery via
this route. In order to develop effective intraductal drug delivery systems, several critical
parameters like particle size and formulation matrix needs to be investigated. To this end,
the major goal of this dissertation is to study the major formulation factors influencing drug
retention vis-a-vis use the findings to develop optimal long-acting intraductal delivery
system for breast cancer.

The specific aims of the dissertation are:
1) To investigate the effect of particle size and formulation on intraductal and lymph
node retention

2) To develop and optimize poly (lactic-co-glycolic acid) formulations of tamoxifen
and determine its pharmacokinetics in rats.

3) To develop and test the pharmacokinetics of long-acting PLGA formulations of 4hydroxytamoxifen
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CHAPTER I

INFLUENCE OF PARTICLE SIZE AND FORMULATION ON BREAST AND
LYMPH NODE RETENTION
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1.1.

BACKGROUND

Localized delivery to the breast through intraductal injections enhanced drug levels in the
breast and reduced systemic exposure. Intraductal delivery (ID) has been effective in
preclinical and clinical studies.

109, 110, 119, 123

Several anticancer drugs (carboplatin,

methotrexate, 5FU, 4-hydroxytamoxifen, paclitaxel) delivered by this route have been
shown to be effective in chemoprevention as well as chemotherapy in both chemical
carcinogenesis as well as transgenic tumor models of breast cancer.

108-110

However, the

major challenge of this approach is the rapid diffusion of drugs out of the ducts into
systemic circulation. In a preclinical study, intraductal doxorubicin exhibited retention
half-life of only 2 hours.22 In another study110, intraductal 5-FU showed superior efficacy
in treated and untreated mammary gland which was attributed to the diffusion of 5-FU into
systemic circulation. In a clinical study 132, carboplatin rapidly distributed into the systemic
circulation after intraductal injection, with a Tmax of ~30 minutes. The systemic and ID
levels were similar in comparison, suggesting that small molecules diffuse rapidly out of
the ducts. In another study, ID administration of PEGylated doxorubicin (liposome)
showed superior efficacy than IV administration.110 The blood level of doxorubicin was
fivefold lower than IV, with no systemic toxicity. However, doxorubicin released from
these liposomes caused local toxicity and edema.

Taken together, there is a need to develop formulations that can prolong and sustain drug
levels in the breast, minimizing systemic side-effects. There have been some recent
attempts to develop approaches to prolong drug retention in the breast. Singh et al
investigated the influence of molecular weight and polymer architecture (Linear 12, 20, 30,
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40 KDa and Two-arm 60 KDa, Four-arm 20, 40 KDa and Eight-arm 20 KDa) to prolong
drug retention in the ducts.

124

The results showed that fluorescent labelled PEG showed

ductal half-life in the range of 7-22 hours, while the half-life of free fluorescein was only
15 minutes. The duct retention half-life increased with an increase in molecular weight (12
– 60 KDa) and the particle sizes of the investigated polymers were in the range of 5-10 nm.
Pharmacokinetic analysis showed a delayed the tmax to 32 ± 13.8 hours with two-arm
60KDa carriers compared to free fluorescein which showed tmax of 0.5 hours. In a
subsequent study22, doxorubicin labelled PEG nanocarriers of higher molecular weight and
branching (40KDa, 4 arm) delayed the t1/2 to 13.1± 3.4 hours compared to free doxorubicin
which exhibited t1/2 of 2.0± 0.4 hours. Histopathological studies showed that PEG
conjugated doxorubicin induced only transient inflammation compared to free intraductal
doxorubicin. Intraductal administration of nanoemulsions111 (<100 nm) were retained in
the rat breast ducts for 120 hours. These nanoemulsions encapsulated a highly hydrophobic
compound ceramide. In vivo whole-body images showed retention of formulations for 120
hours. The improved retention of ceramide in the mammary glands was attributed to the
increased lipophilicity of ceramide (Log P > 6) suggesting improved retention of
hydrophobic compounds in the mammary glands. However, additional studies are required
to investigate the retention of particles of larger size for designing formulations that can
prolong and sustain drug levels in the breast.

The main goal of this study is to investigate the influence of polymeric particles ≥ 100nm
and formulation on intraductal and lymph node retention using fluorescent probes.
Fluorescent labeled polystyrene particles (100-1000nm) were used to study the influence
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of particle size on breast duct retention. To translate the findings to clinical application,
poly lactic-co-glycolic acid (PLGA), a US-FDA approved polymer was used for preparing
nanoparticles (NP), microspheres (MS) and in-situ gel (ISG) formulations. PLGA has been
extensively studied as a drug delivery system due to its biodegradability, tunable
physicochemical properties and the ability to form different delivery systems. 15
Furthermore, there are several PLGA based long-acting parenteral formulations in clinical
use.16 The breast retention and lymph node distribution after ID delivery of different
formulations were studied using in-vitro and in-vivo imaging techniques in rats and pig.

The specific aims of this study are:
1. To investigate the influence of particle size on ductal retention and biodistribution
using polystyrene carriers of different particle size

2. To investigate the influence of PLGA formulations (microparticles, nanoparticles
and in-situ gel) on ductal retention and biodistribution.

1.2.

MATERIALS AND METHODS
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Poly (lactic-co-glycolic acid) (LA:GA = 75:25, 65-75 KDa and 25 KDa, LA:GA = 50:50,
5-10 KDa) was purchased from Akina, Inc. (West Lafayette, IN). Cyanine 5.5 carboxylic
acid (Cy 5.5) was procured from Lumiprobe (Hallandale Beach, FL, USA). The isoflurane
was obtained from VetOne, Boise, ID and Veet hair removing cream was obtained from
Reckitt Benckiser North America (Parsippany, NJ). Polystyrene particles (NIRexTM)
labeled with Near IR dye was obtained from Phosphorex (St. Hopkinton, MA). All other
reagents were purchased from Sigma-Aldrich (St. Louis, MO).
1.2.1. Animals
Female Sprague Dawley Rats (3-4 weeks old) were obtained from USD animal facility and
housed in South Dakota State Animal Resource Wing. The animals were maintained on a
12-hour light/dark cycle in a temperature-controlled environment with food and water were
given ad libitum. The animals were acclimatized for 1 week before starting the study.
For the pig study, 5-6-month-old gilt was procured from South Dakota State University
Swine Education and Research Facility. The animal was maintained on a 12-hour light/dark
cycle in a temperature-controlled environment and fed a standard finisher diet and was
acclimatized for 1 week prior to initiating the study. All animal experiments were
performed with approval from the Institutional Animal Care and Use Committee (IACUC)
at South Dakota State University.

1.2.2. METHODS
1.2.2.1 Preparation of PLGA microparticles
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Microparticles were prepared by oil-in-water (O/W) emulsion method reported in the
literature.

133

Briefly, PLGA polymer (500mg) and Cy5.5 (1mg) were dissolved in 5 ml

methylene chloride (DCM). The organic phase was added dropwise into an aqueous phase
containing 1% PVA. The mixture was then emulsified by homogenized at 10,000 rpm for
1 minute to form o/w emulsion. The resulting emulsion was then stirred at 300-400 rpm
for 3 hours to allow the solvent to evaporate. The microparticles were then separated by
centrifugation at 4000 rpm for 20 minutes. The pellet was washed with distilled water, a
total of three times and freeze-dried. The formulation was stored at 4°C for further studies.
1.2.2.2. Preparation of PLGA nanoparticles
PLGA nanoparticles were prepared by reported emulsion solvent evaporation method. 134
Briefly, 100 mg of PLGA was dissolved in 4ml methylene chloride containing Cy5.5
(1mg). The organic phase was added dropwise into an aqueous phase containing 1% PVA.
This was then sonicated using a probe sonicator set at 50W of energy output for 1 minute
to form oil-in-water (o/w) emulsion. The resulting emulsion was then stirred at 300-400
rpm for 2-3 hours to remove the organic solvent. The nanoparticles were separated by
ultracentrifugation (20,000 rpm) for 20 minutes, washed with distilled water three times.
The pellet was lyophilized and was stored at 4°C for further use.
1.2.2.3. Preparation of PLGA in-situ gel
PLGA in situ gel was formed by phase inversion process, where the polymer in organic
solvent undergoes sol to gel transition on contact with an aqueous medium. 135 In situ gel
was prepared by mixing PLGA of different copolymer ratios and molecular weights in Nmethyl-2-pyrrolidone (NMP) using a previously reported method with slight modification.
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136, 137

PLGA with different copolymer ratios of LA: GA and molecular weights (50:50 and

75:25 of molecular weights 5-10 KDa and 10-15 KDa respectively) were used to prepare
15 wt% in-situ gel to achieve the desired syringeability and sustained release characteristics
for intraductal injection. For forming 15 wt% gel, 75 mg of PLGA 75:25 (10-15 KDa) and
75 mg PLGA 50:50 (5-10 KDa) was weighed into glass vials and dissolved in 1 ml of NMP
by placing on a continuous shaker and kept overnight to completely dissolve the polymer.
Cy5.5 was dissolved in NMP and added into polymer solution and used for in vitro release
studies. For intraductal injection, the polymer was dissolved in NMP overnight and Cy5.5
was dissolved in the polymer solution 30-60 minutes prior to the injection.
1.2.2.4. Characterization of PLGA formulations
The particle size and zeta potential of nanoparticles were measured by DLS on a Malvern
Zetasizer Nano ZS (Malvern Instruments Inc., Southborough, MA). The morphology of
PLGA formulations was characterized using Scanning Electron Microscopy (SEM). The
particle size of microparticles was measured using SEM by measuring the size of 50
particles with Smart Tiff V3 (Carl Zeiss, MA). The ex vivo fluorescence intensity of
formulations was measured using spectrofluorimetry (SpectromaxM2, Molecular
Devices, Sunnyvale, CA) using 690 and 750 nm as the excitation and emission
wavelengths. Encapsulation and loading efficiency of microparticles and nanoparticles
were calculated using the following equation:

Encapsulation Efficiency (%) =

Weight of Cy 5.5 in the formulation
Weight of Cy 5.5 initially added

Loading Percent (%) = Weight of Cy 5.5 in the formulation
Total Weight of the formulation

X 100

X 100
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1.2.2.5. In vitro release study
In vitro release of Cy 5.5. from the formulations were studied using a reported method with
slight modifications.138-140 Briefly, 5-10 mg of microparticles and nanoparticles were
dispersed in 1 ml of release medium (PBS, pH 7.4 containing 1% w/v Tween 80) in an
Eppendorf tube and was placed in an orbital shaker water bath (shaken at 120 per minute)
at 370C. At each time point, the tubes were centrifuged at 10,621 x g for 10 minutes and
1 ml of the supernatant was removed for analysis. The pellet was redispersed in 1 ml of
fresh release medium to maintain the sink conditions. The supernatant was analyzed using
fluorescence spectroscopy to determine the dye concentration in the release medium. For
in-situ gel, 10µg equivalent of the gel was injected into 1 ml release medium using 27 G
needle to form the gel and the release study was carried out as described above.
1.2.2.6. In vivo studies
Intraductal injections were performed using a previously established method. 109 One day
prior to starting the study, rats were anesthetized and hair around the nipple region was
removed using a depilatory cream. Female SD rat was anesthetized using isoflurane and
placed under a surgical microscope. Keratin plug from the mammary gland was removed
by gently holding the nipple using a tweezer and wiping with 70% alcohol. The
formulations were injected using 27-31 G needle into one pair of the inguinal mammary
glands. For lymph node retention studies, thoracic mammary glands were used for
introduction injection, since it drains into the axillary lymph node. This is consistent with
the breast to axillary lymph node drainage in humans. The amount of Cy5.5 (1.5 mcg)
injected was kept constant for all the formulations. For microparticles and nanoparticles,
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0.5 to1.5 mg particles were dispersed in 150 µl of PBS containing 0.05% w/v Tween 80
and vortexed for 30-60 seconds before injection. For in-situ gel, 100 µl of the formulation
was used for intraductal injection. Free Cy5.5 was dissolved in a minimal amount of NMP
followed by dilution with PBS containing 0.05% w/v Tween 80. Similarly, fluorescent
labeled polystyrene particles (1% w/v) were injected into the inguinal mammary gland and
an equivalent amount of the free dye was used for comparison. The animals were
anesthetized and imaged at different time points after injecting the particles using Bruker
In Vivo Extreme II optical system. The animals were then allowed to recover back in their
cages.
For the pig study, the animal was anesthetized by intramuscular injection of TKX (Telazol
and Xylazine at 50mg/ml each and ketamine at 100mg/ml; 2.5m/50kg body weight). The
hair around the nipple region was removed using hair removing cream one day before
starting the study. Before starting the study, alcohol swab (70% ethanol) was used to
remove the keratin plug. The PLGA formulations were dispersed in 500-1000µl of PBS
containing 0.05% w/v Tween 80 and injected into the mammary glands using 27G blunt
needle. Consistent with the 3R (replacement, reduction, and refinement) principles related
to animal use in research, we used one pig to test all the formulations. All seven pairs of
the mammary gland were utilized for the study (Figure S1). Since the mammary glands are
not connected, the chance of spill-over from one mammary gland to another is very limited.
We used 2-3 teats for each formulation and the breast distribution was studied at different
time points (2 hrs and 4 days). At the end of the treatment, the animal was euthanized using
an IV injection of pentobarbital (1ml/10 lb). The mammary glands were excised and
imaged using in vivo imager.
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1.2.2.7. Ex-vivo and In-vivo imaging
The distribution of fluorescently labeled polystyrene particles (0 - 3 days), PLGA
formulations (0 - 4 days) and the free dyes was measured by whole-body imaging using
Bruker In Vivo Xtreme II optical imaging system. In a separate set of experiments, to study
the lymph node retention, the rat was euthanized by CO2 asphyxiation at 2, 24 and 48 hours
to excise the breast and axillary lymph nodes and imaged using in-vivo imager. For
polystyrene particles, the ex vivo and in vivo fluorescence intensity was measured using
the following instrument settings: Excitation/Emission 730/790nm, Bin 1x1 and f stop 1.1.
For in vivo and ex vivo imaging studies of PLGA formulations, the fluorescence intensity
was measured using the following instrument settings: excitation/emission: 690/750nm;
Bin: 1x1 pixels; Exposure time: 20 seconds, f-stop of 1.2, FOV: 19. To compare the
different treatment groups, the data was plotted as percentage of the initial fluorescence
signal against time and the pharmacokinetic parameters (elimination rate constant and
retention half-life) were determined by non-compartmental analysis using PK solutions
software.124 The elimination rate constant (k) was determined from the regression analysis
of semi-logarithmic plot of fluorescence intensity vs time. Retention half-life (t1/2) is
defined as the time at which the fluorescence intensity becomes 50% of the initial value.

1.2.2.8. Mammary whole mount
At the end of the treatment, the rat was euthanized and mammary whole mounts were
prepared using a literature reported method with slight modifications.124 Briefly, mammary
glands

were

dissected

and

mounted

onto

a

glass

slide

and

fixed

in

chloroform/isopropanol/acetic acid (6:3:1) for 6 hours. The glands were then defatted using

59

acetone for 2-3 hours. The slides were then stored in methyl salicylate and the images were
captured using a confocal microscope with 10X objective.
1.2.2.9. Fluorescence microscopy
To visualize the distribution of PLGA formulations in the breast, the rat was euthanized,
and the mammary gland was excised. The tissue was snap-frozen in optimum cutting
temperature (OCT, Tissue Tek, Torrance, CA) medium placed in hexane under liquid
nitrogen. The OCT block was sliced to 8-10 µm thick sections in a cryostat (UV800, Leica
Microsystems, Bannockburn, IL) at -25ºC. The section was dried for 6 hours at 37 ºC and
the coverslip was sealed using CytoSeal (Vector laboratories, Burlingame, CA). The tissue
sections were then observed under an Olympus FluoView 1200 (Center Valley, PA)
confocal laser scanning microscope (excitation/emission wavelength: 682/703 nm) at 20X
magnification.
1.2.2.10. Histology
To test the local tissue toxicity of the formulations, in a separate set of experiments, the
rats were euthanized seven days after intraductal administration of PLGA formulations.
The mammary glands were excised, and the tissue was fixed in 10% buffered neutral
formalin for 24 hours at room temperature. The tissue was embedded in paraffin and 6 µm
sections were prepared using a microtome (Olympus CUT 4060E, Center Valley, PA). The
sections were stained with hematoxylin-eosin and examined under a light microscope
(Olympus AX70, Center Valley, PA) for histological changes at 40X magnification.
1.2.2.11. Statistical analysis
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All the experiments were conducted in triplicates. The data is represented as a mean ±
standard deviation. The groups were compared by Students t-test and One-way analysis of
variance (ANOVA) using Minitab® statistical software (Minitab Inc., State College, PA)
at a significance level of p<0.05.
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1.3. RESULTS AND DISCUSSION
DCIS is confined to the breast and current systemic therapies are associated with significant
physical and emotional distress, impacting the quality of life in women with preneoplasia,
who are otherwise healthy.120,

141, 142

Alternatively, intraductal delivery of anti-cancer

agents through cannulation of the diseased ducts is an effective and safe ‘chemical
mastectomy’ approach for eradicating premalignant lesions with reduced systemic
toxicity.108-110, 113, 123 Poor retention of drugs is a major challenge and it is important to
understand the factors that influence drug retention in the breast to develop effective
formulation strategies for intraductal drug delivery. The main objective of this preliminary
study is to understand the influence of particle size and formulation on retention and
distribution in the breast and regional lymph nodes.
1.3.1. Effect of particle size on breast retention and distribution
To understand the influence of particle size, fluorescent-labeled polystyrene particles in
three size ranges (100, 500 and 1000 nm) were tested. The commercially available
polystyrene particles were used due to their uniform size (Table 8) and its reported use for
in-vitro and in-vivo imaging studies.143 As shown in Figure 7, after intraductal injection in
rats, the nanoparticles and microparticles showed higher retention compared to the free
dye. The fluorescence from the nanoparticles (100 and 500 nm) and microparticles was
observed till 2 and 3 days respectively. On the other hand, there was hardly any
fluorescence observed for the free dye after 6 hours (Figure 7). The results were also
supported by whole-mount imaging studies. The whole-mount images of the

62

breast showed intense fluorescence for the microspheres and there was hardly any
fluorescence seen for the free dye (Figure 8
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Table 8: Characteristics of Polystyrene particles
Particles

Particle Size (nm)

PDI

Zeta Potential (mV)

PS 100 nm

99.21 ± 2.37

0.10 ± 0.03

-53 .3 ± 0.90

PS 500 nm

502.5 ± 4.85

0.18 ± 0.04

-51.26 ± 0.56

PS 1000 nm

1006 ± 3.05

0.32± 0.13

-48.3 ± 0.50

Data is Mean ± S.D (n=3); PS is polystyrene; PDI is polydispersity index
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Figure 7: Representative images (n=3) showing distribution of polystyrene (PS) particles of different particle sizes (100nm,
500nm and 1 µm) in the breast. Free Dye was used as a control. The images were captured using in-vivo imager from 0-72 hours.
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Figure 8: Representative mammary gland whole mount images of rat after treatment with polystyrene (PS) particles and free
dye after 72 hours. The whole mount was imaged under 10X using a confocal microscope.
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The elimination of the particles from the breast decreased with time (Figure 9). The 100 to
500 nm PS particles showed similar retention half-life, but an increase in the particle size
from 500 nm to 1000 nm increased the half-life by five-fold (Table 9). The fluorescence
from the free dye declined rapidly. Based on qualitative analysis, the fluorescence in the
various organs was high with the free dye followed by the 100 nm and 500nm. On the other
hand, relatively lesser fluorescence was observed in the organs for 1000 nm particles
(Figure 10).
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Table 9: Kinetic parameters of Polystyrene particles
Formulation

t ½ (hrs)

Polystyrene 1µm

k (h-1)
0.007 ± 0.0005 ab

94.87 ± 4.12 abc

Polystyrene 500nm
Polystyrene 100nm

0.029 ± 0.002 a
0.033 ± 0.11 a

24.15 ± 3.16 a
22.35 ± 4.72 a

Free Dye

0.662 ± 0.06

1.06 ± 0.16

The data represents mean ± S.D (n = 3). ‘k’ is the elimination rate constant; t 1/2 is the
retention half-life, i.e. time at which the fluorescence intensity is 50% of the initial value.
‘a’ is significant in comparison to Free Dye; ‘b’ is significant to Polystyrene 100 nm; ‘c’
is significant to Polystyrene 500nm. The values are significant at p < 0.05.
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Figure 9: Fluorescence intensity profiles of polystyrene particles (100nm, 500nm and
1µm) expressed as percentage of initial fluorescence. Free dye was used as control. Each
value represents mean ± S.D (n = 3). * is significant compared to free dye (p <0.05).
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Figure 10: Representative ex-vivo fluorescence images of different organs after intraductal injection of polystyrene (PS)
particles (1µm, 500nm and 100nm). The organs and mammary glands were excised and imaged at 72 hours. 1 – liver, 2- spleen,
3- mammary gland, 4- kidneys, 5- lungs, 6- heart)
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Earlier studies have shown that size and polymer architecture influence the formulation
retention in the breast.22, 124 Gu et al showed that the retention half-life of doxorubicin
increased linearly with increase in molecular weight of PEG from 5-40 kDa (hydrodynamic
radius of 3-7 nm).22 The retention half-life ranged from 2 to 13 hours. Similarly, the
retention half-life of fluorescein-conjugated PEG (12-40 KDa; 5-10nm) showed a retention
half-life of 7-22 hours.124 On the other hand, the retention half-life of free dye and
doxorubicin was 15 minutes and 2 hours respectively. 22, 124 Multi-arm (two, four and eightarm) PEG polymers showed similar or lower retention half-life than the linear PEG. 22, 124
Carvalho et al studied the breast retention nanoemulsions (<100nm) in rats. 111, 118 The
nanoemulsions were retained in the breast for up to 5 days with an elimination half-life of
20-30 hours, which is consistent with the half-life observed for 100 and 500 nm particles
in our study. The half-life for the free dye (Alex Fluor) was around 2-3 hours. 118 On the
other hand, the free ceramide was found to be retained in the breast for 48 hours. 111 The
authors did not find any significant difference in the retention between negative and
positively charged nanoemulsions. However, as is evident from these studies, the
physicochemical properties of the molecule including Log P and molecular weight
influence ductal retention in the breast.

Results from our study and the earlier studies suggest that an increase in molecular weight
and particle size limits diffusion through the ducts. Furthermore, hydrophilic molecules are
cleared rapidly from the breast compared to hydrophobic molecules.22, 111, 118, 124 The slower
clearance of hydrophobic molecules can be attributed to the binding to the breast tissue.111
On the other hand, an increase in molecular weight and particle size can limit the diffusion
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through the ducts. Taken together, the results from this study for the first time demonstrate
the retention of particles ≥ 100 nm in the breast.
1.3.2. Preparation and characterization of PLGA formulations.
To develop clinically relevant formulations, we used PLGA, a US-FDA approved polymer.
PLGA is biodegradable which under physiological conditions undergoes hydrolysis
through the labile ester groups. The degradation time can be customized from weeks to
years based on the route and delivery application by adjusting the lactic acid/glycolic acid
ratio and molecular weight.144 Given the versatility of PLGA, it is widely used for sustained
release applications by various routes of administration.

144

In this study, we used Cy 5.5

loaded PLGA microspheres, nanoparticles and in-situ gel for studying the influence of
formulation on breast duct retention.

PLGA microspheres and nanoparticles showed a spherical morphology (Figure 11). PLGA
microspheres and nanoparticles had an average particle size of 8.66 ± 3.25µm and 200 ±
17.08 nm with a low PDI value. (Table 10)
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Table 10: Properties of Cy 5.5 loaded PLGA formulations.
Formulation

Particle size

PLGA
Microparticles

8.66 ± 3.25µm*

Zeta potential
(mV)
-31.75 ± 1.12*

PDI
0.121 ±
0.045*
0.229 ±
0.089

Encapsulation
Efficiency (%)
63.47 ± 2.92*

200 ± 17.08 nm -21.12 ± 2.73
36.02 ± 3.07
PLGA
Nanoparticles
(PDI) polydispersity index; Each value represents mean ± S.D (n = 3); (PDI)
polydispersity index; * is significant compared to PLGA Nanoparticles

Loading
Percent (%)
0.15 ± 0.04*
0.11 ± 0.08
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Figure 11: Scanning electron microscopy (SEM) images of PLGA formulations
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In-situ PLGA gel was prepared by the phase inversion method using NMP as the organic
solvent. When the PLGA suspension in NMP comes in contact with the aqueous fluid in
the injection site precipitates to form a gel.135 NMP is the most commonly used solvent for
in-situ PLGA gels, because of its solvating ability and its safety profile.136 The SEM image
shows the porous structure of the PLGA gel (Figure 11), which is consistent with the
literature.145

One of the goals for developing intraductal formulations is to minimize the frequency of
injections is by sustaining drug release for prolonged periods in the breast. As can be seen
from the in vitro release studies (Figure 12), all the three formulations sustained the release
of Cy 5.5. A biphasic release profile was observed for all the three formulations and the
release profile is consistent with sustained release characteristics of PLGA formulations.
146, 147

A higher burst release was seen with the nanoparticles compared to the other two

formulations. The higher release can be attributed to the larger surface area of the
nanoparticles compared to microparticles.148 On the other hand, there was no significant
difference in the release profile between the microparticles and in-situ gel. Around 40% of
the dye was released in 96 hours from the nanoparticles, while only 8% and 11% of the
dye was released from in-situ gel and microparticles respectively (Figure 12). The slower
release in addition to maintaining the drug levels in the breast can also reduce the local
tissue toxicity of chemotherapeutic agents such as doxorubicin.12
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Figure 12: In vitro release profile of Cy5.5 from PLGA microspheres, nanoparticles and
in-situ gel. The data represents mean ± S.D (n = 3). * is significant in comparison to ISG
(p <0.05)
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1.3.3. Effect of PLGA formulations on retention and distribution in the breast
The next goal was to test the retention and distribution of the PLGA formulations in rat
breast after intraductal injection. Similar to the results from polystyrene particles, the free
dye was cleared rapidly from the breast, while the PLGA nanoparticles were found to be
retained in the breast up to 48 hours (Figure 13). On the other hand, PLGA microparticles
and in-situ gel were retained in the breast for up to 4 days. This was also confirmed from
ex-vivo imaging study of the mammary gland fluorescence from the tissue sections of
excised breast tissue (Figure 14). Unlike the results from the polystyrene study, there was
no detectable fluorescence in the organs for any of the treatment groups at the end of 96
hours (Figure 15). This is not surprising considering the half-life of plasma half-life of Cy
5.5 (2.2 hours).149
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Figure 13: Representative fluorescence images (n=3) depicting intraductal retention of PLGA in-situ gel, microparticles,
nanoparticles and free dye (Cy5.5) at different time points from 0-96 hours. The images were captured using in-vivo imager.
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Figure 14: Representative fluorescence images of PLGA formulations and free dye at the end of study. Ex-vivo images of the
mammary glands were recorded using in-vivo imager. Mammary glands were cryosectioned (8-10 µm) and viewed under 20X
using confocal microscope. The terminal time points were 4 hours for control, 48 hours for PLGA nanoparticles and 96 hours
for PLGA in situ gel and microparticles.
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Figure 15: Representative fluorescence images showing in organ biodistribution of
PLGA in situ gel (ISG), microspheres (MS), nanoparticles (NP) and free Cy5.5 after
intraductal injection in rat. Organs (liver, kidney, lungs, spleen and heart) and mammary
glands were excised and imaged at 60 hours for PLGA nanoparticles, 96 hours for PLGA
in situ gel and microparticles and 4 hours for free Cy5.5.
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The fluorescence in the breast rapidly declined with time for both the free dye and the
nanoparticles, while the decline was slower with microspheres and in-situ gel (Figure 15).
The retention half-life was highest for in-situ gel, which was two-fold higher than PLGA
microparticles (Table 11). The dye diffusion is limited by the higher viscosity of the gel
and increases retention in the duct. The PLGA nanoparticles showed a similar half-life (2024 hrs) compared to polystyrene particles. The half-life for the nanoparticles is comparable
to the half-life observed with nanoemulsions (<100nm).118 Based on our results and results
from earlier studies, some general conclusions can be drawn regarding the effect of particle
size on ductal retention in the breast. 22, 111, 118, 124 The ductal retention half-life of particles
in the size range of 10-500 nm is in the range of 20-24 hrs, while the retention half-life of
microspheres in the size range of 1-9 µm is in the range of 88-95 hrs. As the particle size
increases, the particles undergo hindered diffusion through the ducts. However, further
studies with additional size ranges in the nanometer and micron range are required to
confirm these findings. The higher size range will be limited by the diameter of the ductal
opening (0.5-2 mm) to prevent particles from blocking the duct.118
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Figure 16: Fluorescence intensity profiles of PLGA in-situ gel, microparticles,
nanoparticles expressed as percentage of initial fluorescence. Free Cy5.5 was used as a
control. The data represents mean ± S.D (n = 3). * indicates statistical significance from
free Cy5.5 using students t-test at (p <0.05)
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Table 11: Kinetic parameters of Cy 5.5 loaded PLGA formulations.
Formulation

k (h-1)

t ½ (hrs)

PLGA In situ gel

0.004 ± 0.002 ab

192.5 ± 11.11 ab

PLGA Microparticles
PLGA Nanoparticles

0.008 ± 0.002 ab
0.02 ± 0.001 a

88.35 ± 8.76 ab
24.23 ± 1.12

Cy 5.5

0.40 ± 0.03

1.70 ± 0.16

Each value represents mean ± S.D (n = 3). ‘k’ is the elimination rate constant; t 1/2 is the
retention half-life, i.e. time at which the fluorescence intensity is 50% of the initial value.
‘a’ is significant in comparison to Cy 5.5; ‘b’ is significant in comparison to PLGA
nanoparticles. The values are significant at p<0.05.
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The whole mount showed that the formulations were distributed throughout the ductal tree
(Figure 17). To further confirm that the formulations did not block the duct, we injected
crystal violet along with the three formulations. The formulations did not affect the crystal
violet distribution in the ductal tree, suggesting that the formulations do not block the ducts
in the breast (Figure 18).

Histopathological assessments were performed on H&E stained breast tissue sections to
determine the effect of the formulations on the tissue morphology. Similar to the untreated
mammary gland, ductal architecture was maintained in all the formulations group; there
was no damage to epithelial lining, nor any cellular detachment was observed (Figure 19).
However, scattered inflammatory cells in the surrounding stromal tissue were observed in
the in-situ gel group. Notably, this inflammatory influx was also observed in NMP-treated
group indicating that this minor inflammatory reaction could be possibly attributed to the
solvent (NMP) used for the gel formulation and warrants the need for testing other
alternative solvent-based gel formulations including aqueous-based gels for overcoming
the inflammatory response.
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Figure 17: Mammary whole mount 30 minutes after intraductal injection of free dye and PLGA formulations. The images
were viewed under 20X using confocal microscope.
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Figure 18: Intraductal distribution of crystal violet after mixing with PLGA formulations
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Figure 19: H&E stained sections (5µm) of mammary glands after treatment with PLGA formulations. Images were viewed in
a light microscope under 10X. MS- microspheres; NP- nanoparticles; MG is mammary gland; ISG- in-situ gel; NMP- Nmethyl pyrrolidone.
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Typically, DCIS is localized to a single duct, and therefore it is important to ensure that the
drug distributes to the entire ductal tree including the terminal buds, where the majority of
pre-cancerous lesions begin.120 The diffusion of the formulation can be influenced by the
ductal permeability. Gu et al in a recent study showed that the ductal retention of PEGdoxorubicin conjugate was not significantly different between normal duct and tumor in
the duct in a DCIS rat model.150 However, the ductal permeability can vary with the stage
of the disease.109, 124 The ductal permeability in early stages of DCIS is similar to the normal
ducts but is significantly altered during later stages of tumor development.

109, 124

To this

end, the localized intraductal delivery may be more suited as a chemoprevention strategy
for treating preneoplasia and early-stage DCIS.
The extrapolation of these results to humans should take into consideration the differences
between the rodent and human breast. Rodents have a single duct, unlike multiple ducts in
the human breast. To confirm that the results can be extrapolated to humans, we conducted
a pilot study in pig, which has a much closer mammary gland structure to humans. 151 The
distribution and retention of PLGA formulations in the pig followed a similar trend as
observed with the rat breast (Figure 20). Taken together, the results firmly establish that
ductal retention in the breast can be prolonged by optimizing physicochemical properties
of the formulation.
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Figure 20: Representative fluorescence images (ex-vivo) of porcine mammary glands.
Mammary glands were excised and imaged using in-vivo imager.
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1.3.4. Effect of PLGA formulations on retention and distribution in the regional
lymph node
Breast cancer spreads from the primary tumor to the regional lymph node in the axilla prior
to systemic dissemination.152 Axillary lymph node, which is the main lymphatic basin for
the breast, serves as a reservoir for cancer cells.

152

Therefore, we tested the lymph node

distribution of PLGA formulations after ID injection in rats. Within 1 hour of ID injection,
the PLGA microspheres were found in the axillary lymph node and the fluorescence was
seen up to 2 days (Figure 21). On the other hand, the fluorescence signal from nanoparticles
was detected only up to 24 hours. There was no detectable fluorescence in the in-situ gel
and free dye treatment groups (Figure 21).
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Figure 21: Representative fluorescence images (n=3) of mammary gland, axillary lymph node and organ distribution of PLGA
microparticles (MP), nanoparticles (NP), in-situ gel (ISG) and free Cy5.5 (top to bottom) from 1-48 hours. Images were captured
using in-vivo imager. 1 – liver, 2-spleen, 3- lymph node, 4- mammary gland, 5- kidneys. 6-heart, 7-lungs.
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The lymph node uptake is dependent on the physicochemical properties of the molecule,
vehicle and the route of administration.153 Lymphatic capillaries play an important role in
the uptake of particles and macromolecules through the fenestrations and pores in the
lymphatic capillary walls.

153

Particles in the size range of 100-1000 nm are taken up by

the lymph nodes by pinocytosis.154 However, unlike the microparticles, the nanoparticles
may be washed out relatively faster than from the lymph node.

155

In contrast to the

particulate systems, the in-situ gel is primarily retained in the mammary gland and only the
released dye is transported to the lymph node. Therefore, it is not surprising that there is
no measurable fluorescence in the lymph node with the gel formulation, similar to the free
dye treatment group.

Chemotherapy given through systemic routes does not achieve sufficient concentration in
the lymph nodes.153 Hence, in advanced breast cancer, the regional lymph nodes are
surgically removed and/or subjected to radiation therapy. This is associated with painful
lymphedema.156 The results from this study demonstrate that intraductal delivery of
particulate formulations offers the additional advantage of targeting the lymph node to
prevent metastasis. However, the lymph node uptake can vary with the stage of
cancer.153 Further studies are required to understand the different factors which influence
lymph node distribution after ID injection. Nevertheless, the results serve as a proof of
concept to guide future formulation development for optimizing drug retention in the breast
and regional lymph nodes.
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1.4. CONCLUSIONS
Results from the study demonstrate the effect of formulation on retention in the breast and
lymph node. Microparticles showed longer retention than nanoparticles in the breast and
lymph node. PLGA in situ gel formulation showed the highest retention in the duct among
the formulations tested. Taken together, the results demonstrate the proof-of-concept for
locoregional targeting of breast and lymph nodes by optimal formulation design. Findings
from this study can be used to develop safe and effective localized therapeutic strategies
for breast cancer.
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CHAPTER 2

INTRADUCTAL DELIVERY OF PLGA FORMULATIONS OF TAMOXIFEN
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2.1. BACKGROUND
DCIS accounts for nearly 25% of all the breast cancers diagnosed in the U.S. and affects
nearly 60,000 women each year.

157

Studies suggest that about 20-30% of DCIS will

become invasive cancer even though there are no accurate biomarkers to predict its
potential to progress to the invasive form.

119, 120, 157

Estrogen receptors (ERα) are

overexpressed in 70% diagnosed DCIS cases. Estrogen is a steroid hormone that plays a
major role in the growth and function of the breast and mediates its action through estrogen
receptors (ERα and Erβ). 61, 66

Tamoxifen (TMX) is a selective estrogen receptor modulator (SERM’s), which is widely
used for the treatment of ERα-positive DCIS and invasive cancers. 158, 159 It is also the first
SERM that has been successfully used in the clinic to prevent and treat breast cancer.
68, 159

159

Tamoxifen is estimated to have saved the lives of over 400,000 women with breast

cancer. 160 TMX is a prodrug which requires cytochrome P450 (CYP 450) to convert to its
active metabolites 4-hydroxytamoxifen (4HT) and N-desmethyl-4-hydroxytamoxifen
(Endoxifen) (Figure 22). These metabolites of TMX are 30-100 times more potent than
tamoxifen.

161

One of the seminal chemopreventive trials with TMX in humans was the

National Surgical Adjunctive Breast and Bowel project study (NSABP) chemoprevention
study in the 1970’s. In this study, 13,388 high risk pre- and post-menopausal women were
randomized and treated with TMX or placebo for five years. The results showed a 50%
reduction in invasive cancer and DCIS and a non-significant decrease in bone fractures in
volunteers treated with TMX. 160
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Figure 22: Metabolism of Tamoxifen
Modified from Mürdter, T.E., et al. Clinical Pharmacology & Therapeutics, 89(5), pp.708-717.
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However, oral TMX therapy (20 mg daily for 5 years) is associated with side-effects such
as thromboembolic events and endometrial cancer limiting its use for prevention and
therapy.158 TMX therapy is also linked to drug resistance as they are substrates of Pglycoprotein, breast cancer resistance protein (BCRP) and multidrug resistance associated
protein (MRP) 161-164. TMX has low oral bioavailability and low specificity towards tumor
cells.161 Localized administration of TMX showed reduction in systemic side effects of
TMX.

164, 165

In the present study, we hypothesize that long-acting intraductal TMX

formulations will not only provide a therapeutic advantage by sustaining drug levels in the
breast, but also reduce the side-effects associated with oral TMX.

As described in the previous chapter, PLGA MS and ISG were retained in the mammary
glands for 4 days with reduced systemic exposure compared to PLGA NP and free dye.
Also, we found that PLGA MS and NP was transported and retained in the regional lymph
nodes for 24 and 48 hours respectively. Building on these findings, the main objective of
the present study is to develop intraductal PLGA formulations of TMX and to test the
biodistribution in rats.

The specific aims of the study are:
i)

Development and optimization of TMX loaded PLGA formulations

ii)

In-vitro characterization and release of TMX from PLGA formulations

iii)

Determine the biodistribution of TMX loaded PLGA formulations in rat
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2.2. Materials and Methods
Poly (lactic-co-glycolic acid) (LA:GA = 75:25, 75-85 KDa and 10-15 KDa, LA:GA =
50:50, 5-10 KDa) were purchased from Akina, Inc. (West Lafayette, IN). The isoflurane
was obtained from VetOne, Boise, ID and Veet hair removing cream was obtained from
Reckitt Benckiser (Parsippany, NJ). All other reagents were purchased from SigmaAldrich (St. Louis, MO).

2.2.1. Formulation of PLGA microspheres
Microspheres were prepared by oil-in-water (O/W) emulsion method as described in the
earlier chapter (section 1.2.2.1). To prepare particles of different sizes, homogenization133
(10,000 rpm for 1 minute) and overhead stirring166 (1000 rpm for 10 minutes) were used.
50 mg TMX was used in all the formulations.

2.2.2. Formulation of nanoparticles
PLGA nanoparticles were prepared by emulsion solvent evaporation and sonication
method134 as described in section 1.2.2.2. Tamoxifen was used in different amounts ranging
from 10-50 mg and 100-200 mg PLGA 75:25 (10-15 KDa) were used in the formulations.

2.2.3 Formulation of In situ gel
PLGA in situ gel was prepared using a previously reported method. 137 PLGA in situ gel
(25% w/w) was prepared using PLGA 50:50 (5-10KDa) and PLGA 75:25 (10-15 KDa),
either alone or mixed at 1:1 w/w ratio as described in section 1.2.2.3.
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2.2.4 HPLC
The HPLC analysis of TMX was performed on a Waters system (Milford, MA) equipped
with an isocratic pump, degasser, and autosampler. The compound was separated using a
waters symmetry C18 column (Waters Corporation, Milford, USA) (4.6 mm × 150 mm,
ID 5 μm). The mobile phase for TMX was a mixture of acetonitrile, methanol and water
(7:3:3 v/v) containing 0.1 % v/v acetic acid and 0.01% v/v triethanolamine. The mobile
phase was pumped at a flow rate of 0.8 ml/min and was monitored at 243 nm. The
calibration curve of tamoxifen in acetonitrile (peak area versus drug concentration) was
linear (R2 = 0.999) in the concentration range of 25 to 360 μg/mL for TMX. The data was
analyzed using in built software (Breeze version 3.30 SPA).

2.2.5 Determination of encapsulation and loading efficiency
For determining encapsulation and loading efficiencies, 3 mg of MS and NP was dissolved
in 1 ml of methylene chloride (DCM). The sample was then vortex mixed and sonicated
for 1-2 minutes and the solvent was evaporated to dryness using gentle stream of Argon.
The sample was then reconstituted using 1 ml acetonitrile and 10 µl was injected to RPHPLC determine drug concentrations using conditions as described in section 2.1.4. The
encapsulation and loading efficiencies were calculated using the equation in section 1.2.2.4

2.2.6 In vitro release study
The release study was performed as described in 1.2.2.5. Briefly 10 mg of PLGA
microspheres and nanoparticles were dispersed in 2 ml of release medium (PBS, pH 7.4
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containing 0.5 % w/v SLS) in an eppendorf tube. At each time point, tubes were centrifuged
at 10,000 rpm for 10 minutes. The supernatant was collected (1.8ml) and replaced with
fresh release medium to maintain sink conditions. For, PLGA ISG, 500 µl of formulation
was injected into 4 ml release medium using a 27G needle. At each time point, 2 ml of the
medium was collected and replaced with same volume of fresh release medium to maintain
sink conditions. The supernatant was then analyzed using HPLC as described in section
2.1.4 to determine the TMX concentrations.

2.2.7 In vivo studies
For pharmacokinetic studies, Female Sprague Dawley rats 4-6 weeks old, 150-200 g were
used for the study. All animal studies were performed after getting approval from IACUC
at South Dakota State University. TMX formulations were injected (1 mg x 2 teat) into the
inguinal mammary glands (n=3) for breast retention studies and axillary mammary glands
for lymph node localization studies. Blood samples were (0.5 -0.1µl) were collected from
tail vein at time points (0-14 days). The plasma was separated by centrifuging the tubes
were then centrifuged at 10,000 rpm for 10 minutes. For lymph node localization study,
lymph nodes were excised at time points (0 -14 days). Pharmacokinetics was performed
using PK solutions using non compartmental analysis.

2.2.8 Tissue preparation
Before collecting the organs, the tissues were perfused with saline to remove blood from
the organs. The tissues were weighed and mixed with 0.1mM Tris HCl (0.1 g/ml). The
tissue was homogenized using tissue homogenizer at 10, 000 rpm for 2-3 minutes with
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sample kept under ice. The lymph nodes were homogenized using probe sonicator at 40W
amplitude (2 minutes) in an eppendorf tube kept under ice. Around 100µl of the tissue
homogenate was mixed with 400 µl of acetonitrile (1:4 w/v) to precipitate proteins. The
mixture was vortex mixed for 30 to 60 seconds and further sonicated for 1-2 minutes. The
sample was then centrifuged at 10,000 rpm for 10 minutes. The supernatant was collected
and evaporated to dryness under stream of Argon. The samples were then reconstituted
using 100 µl of 7:3 v/v of ammonium formate and acetonitrile and analyzed using LC-MS.
The same procedure was followed for determining drug concentrations in the plasma.

2.2.9 LC-MS
Tamoxifen and two major active metabolites 4-hydroxytamoxifen and endoxifen were
quantified by Liquid Chromatography Tandem Mass Spectrometry (LCMS) using a
previously reported method.167 Plasma and tissue samples were analyzed using an Agilent
1260 infinity LCMS system (Agilent, Santa Clara, CA, USA). The mobile phase (Table
11) (Mobile phase A was 3.5mM ammonium formate, pH adjusted to 3.5 using formic acid
and mobile phase B was acetonitrile) was pumped through reversed-phase HPLC column
(Agilent Poroshell 120 SB-C18 column (2.1 x 100 mm, I.D 2.7µm) attached to a guard
column (Agilent SB-C18, 2.1 x 5mm, I.D 2.7µm ) at a flow rate 0.5 ml/min using gradient
elution method (Table 12) at 30° C. The volume of injection was 15µl and the needle was
washed using a mixture of acetonitrile methanol and water (7:3:3) before and after each
injection. Detection of TMX and metabolites (4HT and EDX) was performed in positive
ion mode using a single quadrupole mass analyzer. The most intensive signal in the
spectrum was from quasi-molecular ion [M + H]+ and hence the selected monitored ion

101

(m/z) was set to 372, 374 and 388 for tamoxifen, endoxifen and 4-hydroxytamoxifen
respectively. The standard curve range for tamoxifen was 1 ng/ml (LLOQ) to 25 ng/mL;
the range for 4-hydroxytamoxifen was 2.5 ng/ml (LLOQ) to 25 ng/mL; and the range for
endoxifen was 2.5 ng/ml (LLOQ) to 50 ng/ml.

2.2.10 Statistical analysis
All the experiments were conducted in triplicate using three independent batches
of formulations unless noted otherwise. The data is represented as mean ± standard
deviation. One-way ANOVA was performed to determine statistical significance followed
by Bonferroni post hoc analysis at p<0.05.
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Table 12: Gradient elution method for TMX, 4HT and EDX

Time

Flow Rate
(ml/min)

Mobile phase A

Mobile phase B

(Ammonium Formate 3.5mM,
pH 3.5 adjusted with Formic
acid)

100%Acetonitrile

0

70

30

0.250

4

30

70

0.250

4.10

20

80

0.250

8

20

80

0.250

8.10

0

100

0.250

12

0

100

0.250

12.10

30

70

0.250

16

70

30

0.250

16.10

70

30

0.250

22

70

30

0.250
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2.3. RESULTS AND DISCUSSION
The use of systemic therapy is TMX is limited due to its bothersome side- effects.158, 159
Localized delivery of TMX is an effective way to minimize systemic toxicity associated
with TMX. 165 Intraductal delivery has showed enhanced drug levels in the breast in several
preclinical and clinical studies 109, 110, 119, but poor retention of drugs remains a major barrier
for translation of this approach to clinic. 22 A more recent study showed improved efficacy
of fulvestrant in treating ER + breast cancer in two preclinical animal models. 119 However,
the drug was dosed 3-4 times at biweekly intervals to sustain therapeutic levels in the ducts.
Previously, intraductal TMX did not result in chemopreventive effects as no major
metabolites was detected in the mammary glands. However, enhanced retention time of
TMX in the mammary glands and its biotransformation into active forms is not very well
understood. To this end, the major goal of the study is to develop PLGA formulations of
TMX and determine the in vivo biodistribution. This will aid in the development of an
intraductal delivery system that can enhance drug levels in the breast, minimize systemic
exposure and reduce the frequency of intraductal injections.

2.3.1. Preparation and characterization of PLGA microspheres
Poly (lactic-co-glycolic acid) [PLGA] microspheres (MS) were formulated using emulsion
solvent evaporation 168 by homogenization 148 and overhead stirring methods. 166 We chose
PLGA as the delivery system because of its extensive application in drug delivery and is
approved by USFDA. 125 To prepare MS of different particle sizes, PLGA of copolymer
(LA: GA) ratio of 75:25 and molecular weights 10-15 KDa (low) and 75-85 KDa (high)
and two methods, homogenization and overhead stirring were used. With lower molecular
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weight PLGA, homogenization and overhead stirring resulted in the formation of MS with
particle sizes 3.36 ± 1.19 µm and 54.36 ± 12.93µm respectively (Table 13). This was
consistent with previous finding that homogenization results in increased shear and thus
breaks down the emulsion droplets to form particles of smaller size. 169 The drug content
in the MS increased with increase in particle size consistent with previous findings 148. But
when a higher molecular weight PLGA was used, homogenization resulted in lower
particle size of 9.12 ± 3.77 µm and higher drug content

170

Higher molecular weight

polymer has increased viscosity and hence a larger shear is required to breakdown the
droplets to produce smaller particles. PLGA MS with particle size 9.12 ± 3.77 µm showed
a spherical morphology (Figure 24) with higher encapsulation and loading efficiencies
(Table 13). With high molecular weight PLGA, overhead stirring resulted in particles with
particle size was >100 µm, which was deemed not feasible for intraductal injection (data
not shown). Despite variabilities in the duct diameter, it is found that the diameter of the
duct ranges from 0 - 0.2 mm. Previous studies with PLGA microspheres showed that
particle size of 1-10 μm exhibited similar duct retention times. In this study, the goal was
to prepare PLGA MS with particle size ~10μm that can sustain TMX release for 2 weeks.
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Table 13: Characteristics of TMX loaded PLGA microspheres
Formulation

Particle size (µm)

Zeta Potential (mV)

PDI

EE (%)

LE (%)

3.36 ± 1.19

-31.36 ± 0.92

0.44 ± 0.09

55.43 ± 1.95

6.23 ± 0.14

54.36 ± 12.93

-30.48 ± 0.52

0.44 ± 0.09

73.01 ± 3.14

8.89 ± 0.26

9.12 ± 3.77

-28.36 ± 0.74

0.44 ± 0.09

95.35 ± 2.01

10.22 ± 0.12

PLGA 75:25
(10-15 KDa, H)
PLGA 75:25
(10-15 KDa, OH)
PLGA 75:25
(75-85 KDa, H)

PLGA is poly (lactic-co-glycolic acid), LA is lactic acid, GA is Glycolic acid, H is homogenization, OH is overhead stirring.
Data is Mean ± SD. Particle size calculated as an average of 30-50 microspheres using Smart Tiff software. EE is encapsulation
efficiency, LE is loading efficiency, PDI is poly dispersity index
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In vitro release studies were performed for all the three MS formulations described in the
earlier. It is known that smaller particle size tends to release the contents faster because of
the increased surface area. In the present study, PLGA MS with three different particle
sizes (Table 13) were chosen to determine the in vitro release. PLGA MS with particle size
3.36 ± 1.19 µm released TMX in 7 days (Figure 28). PLGA MS of particle size 54.36 ±
12.93 µm sustained the release of TMX >7 days, but the particle size was beyond the size
range for this study. This trend in drug release is because of the larger surface area of
smaller microspheres and shorter diffusion path lengths.

166, 171

However, when a higher

molecular weight of PLGA (75-85 KDa) was prepared using homogenization, the particle
size was determined to be 9.12 ± 3.77 µm. This formulation sustained TMX release for
>20 days and was chosen for in vivo studies (Figure 23). This is due to the slower
hydrolytic degradation of high molecular weight polymer resulting in sustained release of
TMX.

172
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Cumulative Percent Released (%)

PLGA 75-85 KDa, Homogenization, 9.12 µm
PLGA 10-15 KDa, Overhead stirring, 54.36 µm
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PLGA 10-15 KDa, Homogenization, 3.36 µm
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Figure 23: In vitro release of tamoxifen from PLGA microspheres of different particle
sizes. Data is Mean ± SD (n=3)
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Figure 24: Representative SEM images of PLGA formulations
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2.3.1

Preparation and characterization of PLGA nanoparticles

PLGA nanoparticles (NP) were prepared by emulsion solvent evaporation and sonication
method.

134

Previous studies with polystyrene particles showed that particle size of 100-

500 nm exhibited similar retention t ½ in the ducts. So, the goal of the present study was to
formulate PLGA NP of particle size 200-300 nm that can sustain drug release for at least
14 days. Initial optimization studies focused on optimizing the PLGA amounts and
sonication parameters to prepare PLGA NP of this particle size range (data not shown). By
keeping PLGA amount (100mg) and other parameters constant, increasing TMX amount
resulted in increase in the particle size (Table 14). However, by increasing the polymer
amount to 200 mg with 10 mg of TMX resulted in the formation of PLGA NP with particle
size 274.1 ± 6.07 with encapsulation and loading efficiencies of 91.28 ± 2.17 and 6.19 ±
0.17 %. This was consistent with previous findings where an increase in the polymer
amount increased the viscosity of the polymer solution (increased particle size) and
resulted in higher drug encapsulation. 173

The next goal was to determine the formulation that can sustain TMX release for ~14 days
which was the duration of our in vivo study. PLGA NP has higher surface area and higher
drug amounts results in burst release resulting in drug loss. 174 In vitro release of PLGA NP
was performed for 48 hours to optimize the amount of TMX that can be loaded to PLGA
NP (Figure 25). With 50 mg TMX, 80% of TMX was released in 48 hours. By reducing
TMX to 15mg, the TMX release was reduced to ~60%. This was consistent with previous
findings with PLGA nanoparticles134 where higher amounts of drug resulted in a faster drug
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release. However, with 10mg TMX, TMX release was sustained for 2 weeks and was
chosen for further studies (Figure 26). This formulation also exhibited a spherical
morphology (Figure 24) with higher encapsulation and loading efficiencies of 91.28 ± 2.17
and 6.19 ± 0.17 % respectively (Table 14). This formulation was chosen for in vivo study.
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Table 14: Characteristics of TMX loaded PLGA nanoparticles
Amount of

Particle size (nm)

Zeta Potential (mV)

Tamoxifen (mg)

Encapsulation

Loading Percentage

Efficiency (%)

(%)

50

252.2 ± 4.02

-22.14 ± 2.05

77.85 ± 3.78

35.60 ± 6.17

25

234.1 ± 2.01

-20.12 ± 0.09

61.25 ± 4.75

16.78 ± 5.09

15

228.1 ± 9.12

-22.14 ± 1.79

58.04 ± 2.14

7.66 ± 2.45

10*

274.1 ± 6.07

-19.17 ± 3.77

91.28 ± 2.17

6.19 ± 0.17

Data is Mean ± SD, (n=3), PLGA 75:25 (10-15 KDa) amount 100 mg; * indicates PLGA amount of 200mg; PVA was 1%
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25 mg TMX

10 mg TMX

50 mg TMX
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Figure 25: Effect of tamoxifen loading on the burst release of tamoxifen from PLGA
nanoparticles. Data is Mean ± SD, (n=3)
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Cumulative Percentage Released (%)
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Figure 26: In vitro release profile of tamoxifen from optimized PLGA nanoparticles Data
is Mean ± SD, n=3.
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2.3.2

Preparation and characterization of PLGA in situ gel

PLGA in situ gel (ISG) was formulated using NMP as the solvent. NMP was chosen as the
solvent because of its extensive use in the preparation of in situ forming systems and
because of its pharmaceutical precedence.

175

The contact of PLGA ISG with aqueous

medium results in phase inversion and eventually the precipitation of the polymer.
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Initial studies focused on optimizing PLGA ISG with desired viscosity for intraductal
injections. Reducing the polymer concentration decreased the viscosity (Table 15), but
resulted in faster drug release175 (data not shown). Viscosity of PLGA is directly related to
its molecular weight125 and hence PLGA with molecular weights 5-10 KDa and 10-15 KDa
were chosen for the present study.

In vitro release study showed that 20wt% of PLGA 5-10 KDa sustained release for ~10
days (Figure 27). Blending of PLGA of different molecular weights is an effective method
to modulate drug release

137, 146

. In the present study a blend of PLGA 5-10 KDa 10-15

KDa were blended at 1:1 ratio as used to formulate 25 wt% PLGA ISG. This formulation
showed viscosity of 25cP (Table 15) and sustained TMX release for > 20 days and was
chosen for in vivo experiments (Figure 27).
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Table 15: Viscosity of PLGA in situ gel formulations
Formulation

Viscosity (cP)

10 wt% PLGA 50:50 (5-10 KDa)

<12.5

20wt% PLGA 50:50 (5-10 KDa)

25

20wt% PLGA 75:25 (10-15 KDa)

37.5

25 wt% ISG blend
PLGA 50:50 (5-10 KDa) & PLGA 75:25 (10-15 KDa)

25

cP is centipoise. Each value is Mean ± S.D, n=3
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PLGA 5-10 KDa

PLGA Blend

Cumulative percentage Released (%)
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Figure 27: In vitro release profile of tamoxifen from 25 wt% PLGA ISG; PLGA blend is
(5-10 KDa) and (10-15 KDa) at 1:1 wt%. Each Value is Mean ± SD, n=3.
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2.3.4 Effect of PLGA formulations on breast retention and distribution
To study the distribution of PLGA formulations in the breast, we used Poly (lactic-coglycolic acid) PLGA microspheres (MS) and nanoparticles (NP) and in situ gel (ISG). The
formulations were injected into the 2 inguinal mammary glands (1 mg X 2 teats) and the
concentrations of TMX and metabolites in the mammary glands were determined at days
0.5, 1, 2, 4, 6, 7, 10 and 14.

PLGA MS was retained in the mammary gland for 14 days compared to PLGA NP which
was retained for 6 days (Figure 28). This was in accordance with our previous findings
where particle size was found to impact drug retention in the breast. PLGA NP showed
significantly (p<0.05) higher ke (0.0105 ± .002 hrs

-1)

compared to PLGA MS

(0.0012±0.0003 hrs -1) suggesting faster diffusion of PLGA NP from the breast (Table 16).
The diffusion of PLGA MS from the mammary ducts was slower because the larger particle
size offered hindrance to diffusion from the mammary ducts.

22

At day 6, TMX level in

mammary glands treated with PLGA MS were 4-fold and 6-fold higher than PLGA NP
and free TMX respectively (Figure 28). Moreover, the t1/2 and MRT of PLGA MS was
~100-fold higher compared to PLGA NP and free TMX (Table 15)

PLGA ISG was retained in the mammary glands for 14 days and the levels were
significantly higher than PLGA NP and free TMX (Figure 28). The t ½ for PLGA ISG was
significantly higher than PLGA NP and free TMX (Table 16). The amount of TMX in the
breast for PLGA MS and ISG were found to be 1.05µg/mg and 2.20 µg/mg respectively
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after 2 weeks following single intraductal injection. PLGA ISG showed longer retention
times in the breast and was found to have ke of 0.0007 hrs -1 which was lower than PLGA
MS. The MRT of PLGA ISG was found to be 2-fold higher than PLGA MS (Table 16).

Tamoxifen is a prodrug that is metabolically converted to 4-hydroxy tamoxifen176 or can
undergo metabolic conversion to 4-hydroxy N- desmethyl tamoxifen (endoxifen)177 by
cytochrome P450 enzymes 161 (Figure 22). Interestingly, we observed 4-hydroxytamoxifen
in the mammary glands treated with PLGA MS and ISG (Figure 29). The 4HT levels in
the breast was significantly higher (p<0.05) with PLGA MS and ISG compared to free
TMX (Figure 34). The 4HT T

max

for PLGA MS and ISG of were 144 and 168 hours

respectively. Compared to free TMX, the C12hr was ~ 6-fold lower with PLGA MS and
ISG. At day 14, the amount of 4HT in the breast was 1.5 and 3.3-fold higher than free
TMX group for PLGA MS and PLGA ISG respectively (Table 17). No 4HT was detected
in free TMX group and PLGA NP after 48 and 168 hours respectively. In comparison to
PLGA nanoparticles, the level of 4HT for PLGA MS and ISG was significantly higher at
168 hours. Free TMX showed much lower levels of 4HT till 48 hours and was below
detection at later time points. PLGA NP showed 4HT levels till 7 days and was
undetectable afterwards. At day 6, the levels of 4HT in mammary glands treated with
PLGA MS were 5-fold and 2-fold higher than PLGA NP and PLGA ISG. The 4HT level
of PLGA ISG peaked at day 7 with 4-fold higher levels than PLGA MS. At day 14, the
4HT levels in the mammary glands were 1.5-fold and 3.5-fold higher than free TMX.
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Previously (Figure 7), we found that particle size plays a major role in ductal retention.
Also, it is known that hydrophobic drugs are cleared slowly from the breast than
hydrophilic drugs111. Tamoxifen is an extremely lipophilic molecule with Log P value
around 6. The fatty envelope of the breast tissue may serve as a drug reservoir aided by
intra-mammary lymphatic circulation can enhance the drug retention and distribution in
the breast.95 Previously, intraductal TMX did not show chemopreventive effects in MNU
induced rat carcinogenic model. 109 It is fair to conclude that shorter retention time of TMX
in the mammary glands did not facilitate the metabolism of TMX by resident CYP enzymes
in the breast.178 However, in this study PLGA MS and ISG showed retention t ½ >200-fold
higher in the mammary glands compared to free TMX. The CYP 3A4 enzyme is found to
be expressed in the normal breast tissue and in breast tumors and this facilitates the
conversion of TMX in the breast to 4 hydroxy tamoxifen. 178 From our studies, we conclude
that retention of formulation is important determinant for this conversion of TMX in the
breast tissue and PLGA MS and ISG with longer retention times aids in the formation of
4HT in the breast. The role of TMX as an inducer of CYP enzymes in the breast needs also
needs to be considered. 179 The reported IC50 value of TMX in MCF-7 cells is 3.34 – 3.71
µg/ml and clinically relevant concentration in breast cancer patients is 1.85 µg/ml.

180, 181

Results from this study suggests that TMX concentrations were maintained above the
therapeutic levels following single dose of intraductal injection. Moreover, 4HT levels
were maintained above the therapeutic levels of 4HT (IC50 – 1.52 – 6.97 ng/ml)
mammary glands treated with PLGA ISG and MS for 14 days.
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Figure 28: Concentration of tamoxifen in the mammary glands from 12-336 hours. ISG is in-situ gel. Each value is Mean ± SD,
n=3. * is significant in comparison to free tamoxifen treatment group
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Table 16: Pharmacokinetic parameters of tamoxifen in breast
t½

ke

AUC

AUMC

MRT

Free TMX

(hrs)
14.87 ± 0.04

(hrs-1)
0.020 ± 0.0005

(ng. hr/ml)
125355.4 ± 3692.96

(ng. hr2/ml)
3654696 ± 120023.3

(hrs)
26.5 ± 4.3

PLGA NP

28.61± 5.74

0.0105± 0.002

235444.4± 2744.84

9360274.65± 874274.5

39.7± 3.25

a

PLGA MS

204.80±17.33 ab

0.00125±
0.0003 ab

1493077.05± 33219.38 ab

325087882.4± 28461186 ab

217.55±
14.21ab

PLGA ISG

557.13± 52.93

0.0007±
0.0003 ab

2916866.333±197615.3 abc

2116349830±354466261.3 abc

755±108.64 abc

abc

t ½- plasma half-life; ke - elimination rate constant; AUC – area under the curve; AUMC- area under the first moment curve; ;
MRT- mean residence time. TMX- is tamoxifen; NP is nanoparticle; MS is microsphere; ISG is PLGA in-situ gel. a is
significant to Free TMX, b is significant to PLGA NP, c is significant to PLGA MS by One-way Anova followed by Bonferroni
post-hoc test
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Figure 29: Concentration of 4-hydroxytamoxifen in the mammary glands from 12-336 hours. PLGA NP is nanoparticles;
PLGA MS is microspheres; PLGA ISG is in situ gel. Each value is Mean ± SD, n=3. * is significant in comparison to Free
tamoxifen treatment group by One-way Anova followed by Bonferroni post hoc analysis
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Table 17: Pharmacokinetic parameters of 4-hydroxytamoxifen in breast
t½
(hrs)

ke
(hrs-1)

AUC
(ng. hr/ml)

AUMC
(ng. hr2/ml)

MRT
(hrs)

49.06 ± 12.37

0.0064±0.001

88.33±7.07

7689.96±1836.07

86.53±15.83

PLGA NP

59.12 ±23.84

0.005±0.002

365.15±171.19

61320.1±47356.5

154.5±57.27

PLGA MS

116.62±5.64 a

0.002a

1118.35±214.04 ab

239585.9±18355.8 ab

216.6±25.03 a

PLGA ISG

319.34±29.35abc

0.0009±0.0001 a

1959.73±840.76 ab

1365242.6±485313 abc

528.3±67.64 abc

Free TMX

t ½- plasma half-life; ke - elimination rate constant; AUC – area under the curve; AUMC- area under the first moment curve; ;
MRT- mean residence time. TMX- is tamoxifen; NP is nanoparticle; MS is microsphere; ISG is PLGA in-situ gel. a is
significant to Free TMX, b is significant to PLGA NP, c is significant to PLGA MS by One-way Anova followed by Bonferroni
post-hoc test.
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2.3.5 Lymph node localization of PLGA formulations
Regional lymph nodes serve as the primary site for lymphatic drainage from the breast.
Axillary mammary glands were treated with PLGA formulations to test the role of regional
lymph nodes in the clearance of PLGA formulations from the breast. The regional lymph
nodes were excised and analyzed for TMX and metabolites at time points 12, 48, 168 and
336 hours. Results showed that PLGA MS and NP drained to the lymph node and was
retained for 336 hours and 48 hours respectively (Figure 30). At 12 hours, TMX was
detected with the free TMX and PLGA ISG groups and the amounts were not significant,
but no TMX was detected at later time points. At 12 hours, the amount of TMX at regional
lymph nodes was 3-fold higher for PLGA NP and MS respectively compared to the free
TMX. Based on the time points chosen for the present study, PLGA NP was retained for
48 hours and showed 12-fold higher levels at lymph nodes compared to free TMX. The
TMX levels were highest for PLGA MS at 48 hours and this was 5-fold higher than PLGA
NP at 12 hours. The results were in accordance with our observations in the previous
chapter where PLGA MS and NP drained to the axillary lymph node. The presence of
metabolites in the lymphatic system can possibly due to the recirculation metabolites from
the plasma to the lymph nodes (Figures 31 and 32). 183 However, the levels of metabolites
observed were much lower than TMX.

Subcutaneous administration of carboplatin

microspheres was found to sustain drug levels in the lymph nodes. 184. In another study, a
combination therapy of long acting injectable antiretroviral drugs was found to enhance
drug levels in the lymph nodes. The particles are preferentially taken up by more permeable
lymphatic capillaries and can be retained in the lymphatic vessels and transported
throughout the lymphatic system.

The microspheres (<10µm) from the breast are

125

predominantly phagocytosed and transported to the regional lymph nodes. Lymphatic
capillaries play crucial role in uptake of particles (100-1000nm) through pinocytosis.154
The transport mechanism also dictates the lymph node kinetics of microspheres and
nanoparticles. Particles >200nm are exclusively transported to the lymph node by the
dendritic cells.155 Unlike microspheres nanoparticles are washed out much quicker from
the lymph nodes. 155
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Figure 30: Lymph node concentration of Tamoxifen at different time points (12-336 hrs).
Each Value is Mean ± SD, n=3. * is significant in comparison to free tamoxifen treatment
group by One-way Anova followed by Bonferroni post hoc analysis. * indicates
significance compared to free TMX.
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Figure 31: Lymph node concentration of Endoxifen at different time points (12-336 hrs).
Each Value is Mean ± SD, n=3
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Figure 32: Lymph node concentration of 4-Hydroxytamoxifen at different time points
(12-336 hrs).. Each Value is Mean ± SD, n=3
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2.3.6 Systemic distribution
To determine the pharmacokinetics of intraductal TMX, the plasma levels of TMX, EDX
and 4HT were measured from 0-14 days. The plasma level of TMX was lower compared
to 4HT and EDX (Figure 33). Free TMX showed shorter t ½ of 19.51 ± 4.24 hrs for TMX
and was significantly lower than PLGA MS and ISG (Table 18). Also, the C max of TMX
for free TMX was found to be 8.9 ± 1.55ng/ml which was significantly higher (p<0.05)
than PLGA MS and PLGA ISG which was ~3-fold higher than PLGA MS and ISG (Table
18). These results suggest higher systemic exposure of free TMX compared to PLGA MS
and ISG. The plasma t ½ of PLGA MS and ISG ~ 5- fold higher than free TMX which is
due to the higher retention of TMX in the breast resulting in lower amounts of TMX
reaching the systemic circulation. This was consistent with previous observations where
subcutaneously administered tamoxifen loaded MS showed delayed t
microspheres compared to subcutaneous TMX suspensions.

164

½

with PLGA

Moreover, the Tmax for

TMX was in the decreasing order PLGA ISG<PLGA MS<PLGA NP<free TMX (Table
18). The levels of TMX was sustained for 14 days with PLGA MS and ISG with
significantly (p<0.05) higher MRT of 147.73 ± 59.28 and 230.2 ± 0.68 hrs for PLGA MS
and ISG respectively.

The plasma levels of TMX and two major metabolites, EDX and 4HT were in the following
rank order, TMX<4HT<EDX following intraductal administration of TMX. TMX is
converted to metabolites predominantly by the CYP enzymes in the liver and the delayed
t

½

of EDX (Table 20) and 4HT (Table 18) with PLGA MS and ISG suggests a slower
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diffusion of TMX from the breast. PLGA NP showed higher plasma levels of 4HT and
EDX compared to PLGA MS and ISG and was below detection limit after day 5 suggesting
the lower amounts of TMX biotransformed to the metabolites. This was consistent with
our observations in the breast levels of TMX where PLGA NP was retained only for 7 days
with much lower levels than PLGA MS and ISG. EDX is the major metabolite of TMX185
and in the present study TMX levels were found to be lower than metabolites which is
consistent with previous findings. 186 It is not very well understood whether the endoxifen
concentrations accounts for toxicity or treatment outcome in patients taking tamoxifen. 181
In comparison to free TMX, PLGA MS and ISG showed minimal systemic distribution of
TMX and metabolite with highest levels found in the liver. The levels of TMX, EDX and
4HT remained undetectable in the uterus for rats treated with PLGA MS and PLGA ISG.

The TMX metabolic profile in rats resembles to that of humans.

187

However, some

differences have been reported in the metabolic profile of rats and humans. In
biodistribution studies, rat tissues showed equal or higher level of 4HT than endoxifen,
whereas the levels of endoxifen were found to be the most abundant in human tissues. The
apparent volume of distribution for tamoxifen is about 50-60 liters/kg in humans
suggesting extensive tissue binding of tamoxifen 177. In another study, the plasma levels of
tamoxifen and its two metabolites (N- desmethyl tamoxifen and 4-hydroxytamoxifen) was
studied in rat and mouse models in an effort to correlate the levels to human subjects

186

.

This study showed that rats showed similar trends of TMX metabolism and tissue levels
compared to humans. Also, the plasma level of 4HT was comparatively lower than EDX
due to the less dominant 4-hydroxylation pathway in rats. The elimination t1/2 of tamoxifen,
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N-desmethyltamoxifen and 4-hydroxytamoxifen in rats following a single oral dose was
found to be 10.3, 12.1 and 17.2 hrs respectively.

In another study164, tamoxifen loaded PLGA microspheres of varying hydrophobicity’s
were administered subcutaneously in rats with similar levels observed as the present study.
The plasma levels of tamoxifen and 4-hydroxytamoxifen was determined after a single
subcutaneous dose of 11mg/kg tamoxifen. For the most hydrophilic system (PLGA 50/50
microspheres), the maximum concentration of tamoxifen was obtained within 8 hours
reaching levels of 17.1 ng/ml and 4 hydroxy tamoxifen reaching maximum levels of 6.7
ng/ml at 11 hours. For PLGA 50/50 and 75/25 microspheres, the plasma levels of
tamoxifen and 4 hydroxy tamoxifen were 36.14 and 8.5 ng/ml respectively but took longer
time to reach them (23.5 and 215 hours respectively). When tamoxifen in solution was
administered subcutaneously, TMX and 4HT levels were higher (40ng/ml at 8 hours and
24.69 ng/ml at 48 hours respectively). However, on day 4, the presence of tamoxifen and
4HT in plasma decreased and drug was not detected.

The therapeutic levels of 4HT and EDX observed in breast cancer patients taking tamoxifen
(20 mg) are found to be in the range of 0.38 - 6.97 ng/ml and 2.98 - 28.05 ng/ml
respectively.
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Taken together, results show that therapeutic levels of TMX were

maintained in the breast tissue but not in the plasma. However, EDX and 4HT maintained
therapeutic levels in the plasma for PLGA ISG and MS.
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Figure 33: Plasma profile of tamoxifen after intraductal injection of formulations. The plasma concentration was measured for
3 days for free tamoxifen, 5 days for PLGA nanoparticles and 14 days for PLGA microspheres (MS) and in situ gel. ISG is in
situ gel. ISG is in-situ gel. Each value is Mean ± SD, n=3
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Figure 34: Plasma profile of 4-hydroxytamoxifen after intraductal injection of PLGA formulations. The plasma concentration
was measured for 5 days for free tamoxifen, 5 days for PLGA nanoparticles and 14 days for PLGA microspheres and in situ
gel. ISG is in situ gel. ISG is in situ gel. Each value is Mean ± SD, n=3. * Significant in comparison to free Tamoxifen
(p<0.05) by One-way ANOVA followed by Bonferroni post hoc analysis
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Figure 35: Plasma profile of Endoxifen after intraductal injection of PLGA formulations. The plasma concentration was
measured for 3 days for free tamoxifen, 5 days for PLGA nanoparticles and 14 days for PLGA microspheres and in situ gel. ISG
is in situ gel. Each Value is Mean ± SD, n=3.
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Table 18: Pharmacokinetic parameters of tamoxifen in plasma

Cmax
(ng/ml)

Tmax
(hrs)

Free TMX

8.9 ± 1.55

0.3

PLGA NP

6.9 ± 2.1

8 ± 3.4 a

PLGA MS

2.9 ± 0.72 ab

72 ab

PLGA ISG

3.63 ± 0.15 a

80 ±27.71
ab

ke
(hrs-1)

t½
(hrs)

0.015 ± 0.002 19.51 ± 4.24
0.0066 ±
0.003 a

56.75 ± 35.33

AUC
(ng. hr/ml)

AUMC
(ng. hr2/ml)

MRT
(hrs)

115.8 ± 43.31

4546.37 ±
466.103

38.6 ± 13.10

260.9 ± 35.41

12666.2
±
*
466.10

47.7 ± 3.15

34635.5 ±
25952.3
136427 ±
76773.6 ab

147.73 ± 59.28

0.0033 ± 92.89 ± 26.08 a 211.23 ± 89.43 a
0.0009 a
0.0028 110.75 ± 31.15 a 575.96 ± 88.14
±0.0007 a
abc

ab

230.2 ± 0.68 ab

t ½- plasma half-life; ke - elimination rate constant; Cmax – peak plasma concentration; Tmax- time to reach peak plasma
concentration; AUC – area under the curve; AUMC- area under the first moment curve; ; MRT- mean residence time. TMX- is
tamoxifen; NP is nanoparticle; MS is microsphere; ISG is PLGA in-situ gel. a is significant to Free TMX, b is significant to
PLGA NP, c is significant to PLGA MS by One-way Anova followed by Bonferroni post-hoc test.
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Table 19: Pharmacokinetic parameters of 4-hydroxytamoxifen in plasma

Free TMX

Cmax
(ng/ml)
4.2 ± 0.115

Tmax
(hrs)
1

Nanoparticles

3.1 ± 0.36 a

4.6 ± 3.6

Microspheres

2.36 ± 0.26 ab

ke
t½
(hrs-1)
(hrs)
0.0204 ± 0.011 33.16 ± 20.20
0.0077 ±
0.0003

38.51 ± 1.83

112 ± 42.33 0.002 ± 0.0004 157.11 ± 26.29
ab

ISG

2.36 ± 0.17 ab 224 ± 42.33 ab

0.0037 ±
0.0011

94.27 ± 23.52

ke
(hrs-1)
0.0204 ±
0.011

AUC
(ng. hr/ml)
92.56
± 19.45

AUMC
(ng. hr2/ml)
4153.8 ±
1094.60

MRT
(hrs)
43.56 ±
3.19

0.0077 ±
0.0003

168.1 ± 1.80 a

14150.3 ±
1373.2

84.03 ±
7.39

0.002 ±
0.0004

679.2 ±
169.94 ab

188094.86 ±
77107.74

252.03 ±
49.79 ab

0.0037 ±
0.0011

813.06 ±
97.36 ab

220136.53 ±
52211.86 a

264.66 ±
32.21 ab

t ½- plasma half-life; ke - elimination rate constant; Cmax – peak plasma concentration; Tmax- time to reach peak plasma
concentration; AUC – area under the curve; AUMC- area under the first moment curve; ; MRT- mean residence time. TMX- is
tamoxifen; NP is nanoparticle; MS is microsphere; ISG is PLGA in-situ gel. a is significant to Free TMX, b is significant to
PLGA NP, c is significant to PLGA MS by One-way Anova followed by Bonferroni post-hoc test

137

Table 20: Pharmacokinetic parameters of endoxifen in plasma

Cmax
(ng/ml)

Tmax
(hrs)

Free TMX

11.1 ± 1

2

Nanoparticles

4.76 ± 0.26 a

1

Microspheres

5 ± 1.10 a

2.33 ± 0.88

ISG

5.36 ± 1.10 a

2

ke
(hrs-1)

AUC
(ng. hr/ml)

AUMC
(ng. hr2/ml)

MRT
(hrs)

0.0142 ± 0.0127 34.19 ± 25.42

174.26 ± 19.38

8312.83 ±
2050.43

46.4 ± 5.95

0.0083 ± 0.0012 37.92 ± 6.43

219.5 ± 22.3

9967 ± 1628.2

44.9 ± 2.6

247.27 ±
90.59

2177.63 ± 580.41

1155923.16 ±
594100.43

472.56 ± 124.02

292.30 ±
112.05

3125.06 ± 1050.41

2279641.4 ±
1447487.3

592.93 ± 205.86

0.0013 ± 0.0003
0.0013 ± 0.0003

t½
(hrs)

ab

ab

ab

t ½- plasma half-life; ke - elimination rate constant; Cmax – peak plasma concentration; Tmax- time to reach peak plasma
concentration; AUC – area under the curve; AUMC- area under the first moment curve; ; MRT- mean residence time. TMX- is
tamoxifen; NP is nanoparticle; MS is microsphere; ISG is PLGA in-situ gel. a is significant to Free TMX, b is significant to
PLGA NP, c is significant to PLGA MS by One-way Anova followed by Bonferroni post-hoc test.

ab
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2.3.7 Organ distribution of TMX
To determine the biodistribution of PLGA formulations, the organs were collected at the
end of the study and the concentrations of TMX, 4HT and EDX were determined. Free
TMX showed significantly higher systemic exposure of TMX compared PLGA MS and
ISG (Figure 36). PLGA MS and ISG showed significantly (p<0.05) lower systemic
exposure of TMX in all organs compared to free TMX. The levels of TMX in the liver and
uterus for free TMX was ~10 fold and 3-fold higher compared to PLGA MS and ISG.
PLGA NP showed higher systemic TMX levels than PLGA MS and ISG with higher drug
levels present in the lungs and liver.
The organ distribution of EDX was significantly lower for PLGA MS and ISG compared
to free TMX (Figure 37). EDX levels were ~3 fold lower with PLGA MS and ISG
compared to free TMX. The higher levels of EDX can be due to the relatively higher
circulating levels of EDX in the plasma. EDX was found in the highest level in all the
organs (Figure 37). The systemic exposure of 4HT was found to be lower than EDX with
higher levels present in the liver were higher than TMX (Figure 38). The 4HT organ
distribution with the free TMX group was significantly different (p<0.05) compared to
PLGA MS and ISG. Both the metabolites remained undetectable in the uterus for PLGA
MS and ISG while free TMX showed ~6 fold and ~3-fold higher levels of EDX and 4HT
with free TMX.
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Figure 36: Biodistribution of tamoxifen after intraductal administration of PLGA
formulations. Each value is Mean ± SD, n=3. * is significant compared to free TMX
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Figure 37: Biodistribution of endoxifen after Intraductal administration of PLGA
formulations. Data is Mean ± SD, n=3.* is significant in comparison to free TMX.
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Figure 38: Biodistribution of 4-hydroxytamoxifen after Intraductal administration of
PLGA formulations. Each value is Mean ± SD, n=3. * is significant compared to free
TMX.
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2.4 Conclusions
Tamoxifen (TMX) loaded PLGA microspheres (MS) were formulated with particle size
9.12 ± 3.77 µm with loading and encapsulation efficiencies of 10.22 ± 0.12% and 95.35 ±
2.01% respectively. This formulation sustained TMX release for ~3 weeks. PLGA
nanoparticles were formulated with loading and encapsulation efficiencies 6.19±0.17 and
91.28±2.17% respectively. The optimized formulations sustained TMX release for ~2
weeks. 25 wt% PLGA in situ gel with polymer blends resulted in low viscous (25cP)
formulations and sustained TMX release for ~3 weeks. PLGA MS and ISG were retained
in the mammary glands for 2 weeks and showed >200-fold higher t½ compared to free
TMX. The levels of TMX in the mammary gland were maintained above the therapeutic
levels of TMX for 2 weeks. PLGA MS and ISG generated 4-hydroxytamoxifen in the
mammary glands at levels above the therapeutic levels of 4HT for 2 weeks. PLGA MS and
ISG showed lower TMX levels in the plasma (<5ng/ml) for 2 weeks. The systemic
exposure of free TMX was significantly higher with TMX, EDX and 4HT compared to
PLGA MS and ISG. PLGA MS and NP was transported to the regional lymph nodes and
was retained for 2 and 14 days respectively with levels significantly higher (p<0.05) than
Free TMX. Taken together, PLGA MS and ISG formulations enhanced TMX and 4HT
retention in the mammary glands for 2 weeks. These formulations resulted in lower
systemic exposure and PLGA MS and NP can potentially target regional lymph nodes.
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A summary of the findings from this chapter is depicted below.

Figure 39: Summary of findings from this chapter
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CHAPTER 3
INTRADUCTAL FORMULATIONS OF 4-HYDROXYTAMOXIFEN
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3.1. BACKGROUND
For more than 25 years, TMX has been the gold standard for endocrine treatment for all
cases of estrogen receptor (ER) positive breast cancer. TMX is also the first SERM that
has been successfully used in the clinic to prevent and treat breast cancer.

159

TMX is a

prodrug which is extensively metabolized by cytochrome P450 enzymes to form
metabolites with higher potencies towards estrogen receptors. 4HT is formed by 4hydroxylation of tamoxifen requires CYP3A4 for its metabolic conversion.

188

It is

reported to have 100-fold more affinity towards ER and 30-100 fold more potent than TMX
in suppressing estrogen dependent cell proliferation.

176

EDX is another major metabolite

of TMX which has higher potency than the parent compound. 181
Sukumar et al

109

, investigated chemopreventive effects of intraductal TMX in estrogen

receptor–positive, MNU-induced rat mammary tumor model. Intraductal TMX did not
show any chemopreventive effect as the metabolic conversion relied mainly on the CYP
enzymes in the liver. 189 However, results from the previous chapter suggest that increased
drug retention time in the mammary gland will likely have an effect on metabolic
conversion of prodrugs like TMX in the breast. The study reports rapid diffusion of small
molecules out of the ducts and hence the chemopreventive effects of 4HT might be limited
because of poor drug retention in the mammary glands. CYP450 is a key enzyme for
metabolic activation of TMX and genetic polymorphism of CYP enzymes influences the
plasma concentrations of metabolites and clinical outcomes of patients treated with TMX.
188

Intraductal 4HT further offers the advantage of treating patients who are susceptible to

genetic polymorphisms of CYP enzymes. Taken together, the main goal of the study is to
develop long-acting formulations of 4HT and study in vivo biodistribution.
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Based our results from the previous chapter, PLGA MS and ISG were retained in the
mammary glands for 14 days. However, PLGA ISG showed signs of local inflammation,
likely from the organic solvent (NMP). Therefore, our goal was to develop an aqueous gel
to address this issue. Thermoresponsive in situ hydrogels are attractive options for long
term release of drugs.

190, 191

These are liquid at room temperature and forms a gel at the

body temperature192.

PLGA-PEG-PLGA is an ABA-type triblock copolymer and is the most widely studied
thermosensitive gel because of its biodegradable and nontoxic properties. 193 However, for
prolonged release, PLGA block is replaced with poly lactic acid (PLA), poly (ecaprolactone) (PCL) and poly (e-caprolactone-co-lactide) (PCLA) blocks. The degradation
times for PCLA-PEG-PCLA is much slower than PLGA-PEG-PLGA. Also, the use of CL
(e-caprolactone) instead of LA could reduce the effect of acidic degradation products that
can arise from using PLA alone. 193-195 In our previous study with TMX, MS and ISG alone
sustained drug release for ~2 weeks. In the present study, the goal was to further prolong
the retention of 4HT in the mammary gland. The combination of micro or nanocarriers in
thermosensitive hydrogels have been reported to further sustain drug release.196-198 Hence,
we chose a combinatorial approach of dispersing PLGA MS in PCLA-PEG-PCLA
thermogel to extend the drug release and retention.
The specific aims of the study are:
i)

To develop 4HT loaded PLGA microspheres in PCLA-PEG-PCLA thermogel

ii)

Determine the pharmacokinetics of 4HT MS in gel (MSG) in rats
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3.2. Materials and Methods
PCLA-PEG-PCLA (1700-1500-1700) were purchased from Akina, Inc. (West Lafayette,
IN). All the other chemicals were similar to chapters 1 and 2.
3.2.1. Formulation of PLGA microspheres
Microspheres were formulated as described previously in sections 1.2.2.1 and 2.2.1 using
50 mg 4-hydroxytamoxifen.
3.2.2. Determination of encapsulation and loading efficiency
The encapsulation and loading efficiencies were determined as described previously in
section 2.2.5.
3.2.3. Formulation of PLGA microspheres in PCLA-PEG-PCLA thermogel
To make the thermogel, the PCLA-PEG-PCLA (1700-1500-1700) was weighed and added
to ultrapure DI water to attain a final concentration of 25 % w/v.
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The solution was

stirred for 24 hours at 2-8 ºC. PLGA microspheres were dispersed into PCLA-PEG-PCLA
by gentle vortex mixing for 5-10 seconds. Different weight ratios of thermogel and MS
were tested for optimal gelling at 37°C. Optimized PLGA microspheres (mg): PCLA: PEG:
PCLA (mg) ratio: 1:10 w/w. Vial tilt method199 was used to confirm the gelling of the
polymer at 37ºC. The formulations were transferred to a glass vial and were incubated at
37°C for 10 minutes. Gelling was confirmed if there was no flow of the formulation after
inverting the tube for 60 seconds.
3.2.4. In vitro release study
PLGA microspheres containing 300 μg 4HT were dispersed in 25% w/v PCLA-PEGPCLA thermogel at 1:10 % w/w

ratio into a 2 ml Eppendorf tube. The formulation was
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gently vortexed for 5-10 seconds to disperse the microspheres in thermogel. The
formulation was incubated at 37°C for 10 minutes and allowed to gel. Afterwards, 2 ml of
pre-warmed release medium (PBS, pH 7.4 containing 0.05 % w/v SDS) was gently added
on top of the gel. The tube was placed in an incubator shaker (50 rpm) and 1.8ml of release
medium was drawn at each time points and replaced with fresh release medium to maintain
sink conditions. The supernatant was then analyzed using HPLC as described in section
2.2.6.

For thermogel alone, 4HT was dissolved in methanol and 300μg of 4HT was added to the
thermogel and the release study was performed as described earlier. For PLGA
microspheres, microspheres containing 300 μg of 4HT was dispersed in 2 ml release
medium (PBS, pH 7.4 containing 0.05 % w/v SDS). At each time point, the tubes were
centrifuged at 10,000 rpm for 10 minutes. The supernatant (1.8 ml) was collected and
replaced with fresh release medium to maintain sink conditions. The drug concentration
was determined using HPLC at γ max 243nm as described in section 2.2.4.

3.2.5. In vivo studies
In vivo studies were performed as described previously in section 2.2.7. For
pharmacokinetic studies, Female Sprague Dawley rats 4-6 weeks old, 150-200 g were used
for the study. 4HT formulations were injected (300µg x 2 teat) into inguinal mammary
glands for breast retention studies and into the axillary mammary glands (n=3) for lymph
node localization studies. All the animal studies were performed after getting approval
from the IACUC at South Dakota State University.
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3.2.6. Sampling and tissue preparation
The sampling and tissue preparations were performed using the same methodology as
described previously in section 2.2.8.

3.2.7. LC-MS
LCMS method using gradient elution was the same as described previously in section 2.2.9

3.3 . RESULTS AND DISCUSSION
3.3.1. Preparation and characterization of formulations
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In the present study we chose PLGA of molecular weight 75-85KDa and used
homogenization to formulate microspheres of particle size 9.63 ±1.49 µm (Table 21). This
formulation resulted in microspheres with spherical morphology (Figure 40), higher drug
content (10.46 ± 0.38 %) and encapsulation efficiency (92.46 ± 2.59).This is consistent
with previous findings in which a highly lipophilic drug like 4HT (Log P = 6) tends to
show higher entrapment in hydrophobic PLGA matrix.97, 200 PCLA-PEG-PCLA thermogel
was chosen as the gel matrix to disperse PLGA MS owing to its slower degradation and
ability to sustain drug release.

In the present study, we chose a biodegradable, thermoreversible triblock copolymer poly
(ɛ-caprolactone-co-lactide)-b-poly (ethylene glycol)-b-poly (ɛ-caprolactone-co-lactide)
(PCLA–PEG–PCLA) as month long release profile was preferred. 199 The concentration of
PCLA-PEG-PCLA thermogel was 25% w/v. Moreover, thermogel chosen for this study
offer the benefit of lower viscosity in their sol state with slower degradation rates. 201 This
is critical for intraductal injections where a lower viscosity with sustained release profile
is preferred. Several ratios were tried to optimize the amount of 4HT loaded MS that can
be dispersed in thermogel (data not shown). Optimized ratio of 4HT loaded MS and PCLAPEG-PCLA was determined to be 1:10 w/w. Vial tilting method199 was performed to
visually characterize the sol to gel transition after incubation at 37 ºC for 10 minutes. The
image (Figure 41) shows the sol to gel transition of MSG after incubation of the
formulation for 10 minutes at 37 ºC.
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Table: 21. Formulation characteristics of 4HT loaded PLGA microspheres
Formulation

Particle size (µm)

Encapsulation Efficiency (%)

Loading Efficiency (%)

PLGA Microspheres
(LA:GA-75:25),
Mw – 75-85KDa

9.63 ± 1.49

92.46 ± 2.59

10.46 ± 0.38

PLGA is poly (lactic-co-glycolic acid), LA is lactic acid, GA is Glycolic acid, Mw is molecular weight.
Each value represents Mean ± S.D, n=3.
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Figure 40: Scanning electron microscopy image of 4HT loaded PLGA microspheres
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Figure 41: PLGA microspheres dispersed in PCLA-PEG-PCLA thermogel before
(left))and after (right) incubation at 37°C.
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3.3.2 In vitro release
The PLGA MS and thermogel released 4HT for ~ 3 weeks. On the other hand, MSG
sustained 4HT release >4 weeks (Figure 42). PLGA MS showed a highest burst release
resulting in ~ 30% of 4HT released in 48 hours. Thermogel showed lower burst release
(~16 %) compared to MS alone. MSG showed the lowest burst release of 4HT and resulted
in ~ 4 fold reduction compared to PLGA MS alone and ~ 2 -fold reduction compared to
thermogel (Figure 42). The MSG sustained 4HT release for >30 days. Similar observations
were made previously where microspheres when combined with thermogel system resulted
in drug release of >30 days.

191

barrier long-acting formulation.

Microspheres dispersed in thermogel provides a dual
196-198

and sustained drug release longer than MS or

thermogel alone. MSG formulation was chosen for in vivo studies.
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Figure 42: In vitro release profile of 4-hydroxy tamoxifen from PLGA microspheres,
Thermogel is PLGA microspheres dispersed in PCLA-PEG-PCLA thermogel; MS is
microspheres; PLGA is poly (lactic-co-glycolic acid). Data is Mean ± SD, n=3
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3.3.3. Pharmacokinetics and in vivo biodistribution
To study the pharmacokinetics, MSG and free 4HT in corn oil was injected into two
mammary glands (300 µg per teat x 2 teats) and the concentrations of 4HT and EDX were
measured from 0-14 days. The duration study was consistent with previous study with
TMX. The axillary mammary glands were chosen to study the lymph node localization of
4HT.

MSG sustained plasma levels for both 4HT and EDX for 14 days, while no 4HT or EDX
was detected with free 4HT after days 7 and 9 respectively (Figures 43, 44). For free 4HT,
the plasma t ½ was 31.83 ± 8.08 hrs and this was significantly shorter (p<0.05) than MSG
(104.12 ± 18.30 hrs). The elimination rate constant (ke) for MSG was also significantly
(p<0.05) lower in comparison to free 4HT (Table 22) suggesting a slower diffusion of 4HT
from mammary glands treated with MSG.

This was also evident from the plasma

concentrations where free 4HT showed higher peak plasma levels compared to MSG. Free
4HT exhibited a higher Cmax of 29.7 ± 2.9 ng.hr/ml and was reached earlier (T max of 2 hrs)
compared to the Cmax observed with MSG (21.5 ± 3.01 ng.hr/ml) with a delayed T max (72
hrs). 4HT was undetectable in the free 4HT group after day 7 (Figure 43), whereas MSG
prolonged 4HT levels for 14 days (Figure 43) in the plasma. Similarly, other
pharmacokinetic parameters such as AUC0-α and MRT for 4HT were significantly higher
for MSG suggesting longer retention of drug in the plasma (Table 22).
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EDX is a major metabolite of 4HT and requires CYP enzyme system for its metabolic
conversion. 202 EDX levels were found to be higher in the plasma for both free 4HT and
MSG (Table 22). The Cmax for EDX for free 4HT was higher than MSG (Table 23). Free
4HT showed significantly lower (p<0.05) t

½

for EDX (45.43 ± 22.42 hrs) compared to

MSG (302.58 ± 41.91 hrs). For free 4HT, no EDX was detected after day 9 (Figure 41),
while MSG sustained EDX concentration in the plasma for 14 days (Figure 42).

The therapeutic levels of 4HT and EDX in the plasma observed in breast cancer patients
taking tamoxifen (20 mg) are found to be in the range of 0.38 - 6.97 ng/ml and 2.98 28.05 ng/ml respectively. The reported IC50 values of 4HT and EDX on MCF-7 cells are
reported to be 1.52 - 6.97 ng/ml for 4HT and 2.98 – 70.19 ng/ml for EDX. 182 In the
present study, MSG sustained both 4HT and EDX levels within the range of the reported
IC50 value for both the drugs. Taken together, MSG sustained therapeutic levels of EDX
and 4HT in the plasma.

At day 14, the concentration of 4HT retained in the mammary gland was 5-fold higher than
free 4HT (Figure 43). No 4HT was detected with free 4HT at day 14. EDX was detected
in the mammary glands treated with MSG at day 14 (Figure 44). Previously, intraductal
4HT did not result the formation of EDX in the mammary glands.109 However, results from
this study suggest that formulations that can sustain 4HT levels in the mammary glands is
a critical factor for conversion of 4HT to EDX. Moreover, the levels of EDX in the
mammary glands treated with MSG was much higher than the reported IC50 value of EDX
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in MCF-7 cells181. This was consistent with our observations in the previous chapter where
TMX was converted to 4HT in the mammary glands by CYP enzymes178 treated with MS
and ISG.

In vivo biodistribution study after 14 days showed higher levels of EDX compared to 4HT
for MSG (Figure 50). No uterine exposure was detected with MSG. At day 14, no 4HT or
EDX were detected in organs treated with free 4HT suggesting faster clearance of EDX
and 4HT compared to MSG. Lymph node localization study showed that 4HT was
transported to the regional lymph nodes and was retained for 14 days in rats treated with
MSG (Figure 45). No 4HT was detected in the lymph nodes in free 4HT group. This was
consistent with our previous findings where PLGA MS was localized in the regional lymph
nodes for 14 days. With MSG, PLGA MS might have possibly diffused out of the gel
matrix and transported to the regional lymph nodes. No 4HT was detected in the regional
lymph nodes treated with free 4HT. The levels of 4HT observed in the regional lymph
nodes were higher than the IC50 value for 4HT on MCF- 7 cells suggesting its clinical
significance. Taken together, MSG sustained therapeutic levels of 4HT and EDX in the
plasma and mammary glands. Also, PLGA MS from the MSG was transported and retained
in the regional lymph nodes for 14 days.
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Figure 43: Plasma drug profile of 4-hydroxytamoxifen and endoxifen following treatment with free 4-hydroxytamoxifen
formulation. Each data point is Mean ± SD, n=3. The concentration 4-hydroxytamoxifen was undetectable after day 7 and
endoxifen was undetectable after day 9. The two groups are not statistically significant by Students t-test (p<0.05)
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Figure 44: Plasma drug profile of 4-hydroxytamoxifen and endoxifen following treatment with microspheres in thermogel
formulation. Each data point is Mean ± SD, n=3.* is significant by Students t-test (p<0.05).
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Table 22: Pharmacokinetic parameters of 4-hydroxytamoxifen in plasma
Pharmacokinetic parameters of 4-hydroxytamoxifen
t½
(hrs)

ke
(hrs-1)

Cmax
(ng/ml)

Tmax
(hrs)

AUC
(ng. hr/ml)

AUMC
(ng. hr2/ml)

MRT
(hrs)

Free 4HT

31.83 ± 8.08

0.009 ± 0.002

29.7 ± 2.9

2

1156.53 ± 4.36

72813.93 ± 4744.79

63.4 ± 4.85

MS in
Thermogel

104.12 ± 18.39*

0.002 ±0.0004*

21.5 ± 3.01*

72*

2590.3 ± 261.57*

465544 ± 103516.95*

182.66 ± 55.98*

t ½- plasma half-life; ke - elimination rate constant; Cmax – peak plasma concentration; Tmax- time to reach peak plasma concentration; AUC – area under
the curve; AUMC- area under the first moment curve; ; MRT- mean residence time. MS is microspheres; Data is Mean ± SD, n=3; * is significant by
Students t-test (p<0.05)

Table 23: Pharmacokinetic parameters of endoxifen in plasma
Pharmacokinetic parameters of Endoxifen

Free 4HT
MS in
Thermogel

t½
(hrs)
45.43 ± 22.42

ke
(hrs-1)
0.007 ± 0.002

Cmax
(ng/ml)
49.7 ± 13.5

Tmax
(hrs)
24

AUC
(ng. hr/ml)
1978.76 ± 97.32

AUMC
(ng. hr2/ml)
174361.1 ± 45850.24

MRT
(hrs)
87.53 ± 18.63

302.58 ± 41.91*

0.0009 ±
0.0001*

38.5 ± 0.73

88 ±
13.85*

8145.8 ±
1465.92*

2710550.93 ± 1064850.69*

324.3 ± 74.96*

t ½- plasma half-life; ke - elimination rate constant; Cmax – peak plasma concentration; Tmax- time to reach peak plasma concentration; AUC – area under
the curve; AUMC- area under the first moment curve; ; MRT- mean residence time; MS is microspheres; Data is Mean ± SD, n=3; * is significant by
Students t-test (p<0.05)
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Figure 45: Organ levels of 4HT at the end of study (14 days). Data is Mean ± SD, n=3.

250

Endoxifen

Concentration (ng/mg)

200

150

100

50

0
Mammary
gland

Lymph
node

Liver

Spleen

Kidney

Lungs

Heart

Uterus

Figure 46: Organ levels of EDX at the end of study (14 days). Data is Mean ± SD, n=3..
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3.3.4 Time dependent breast distribution study
To determine the extent of drug retention in the breast, the mammary gland levels of 4HT
and EDX were measured on days 7, 14 and 28. Results showed that MSG retained 4HT
for 28 days compared to free 4HT (Figure 47). Free 4HT was retained in the mammary
glands for 7 days even though the levels were >10 fold lower as observed with MSG
(Figure 47). This can be due to the highly lipophilicity of 4HT and the vehicle (corn oil)
resulting in drug binding to the adipose tissue in the breast.

97

At day 7, the 4HT

concentration was 12-fold higher with MSG compared to free 4HT. At day 28, MSG
maintained 4HT concentration of 1.06 µg/mg, which is higher than the reported IC50 value
of 4HT for MCF-7 cells. 182

EDX was generated in the mammary glands treated with MSG possibly due to the
biotransformation of 4HT by resident CYP enzymes present in the mammary glands.
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The mammary gland levels of EDX were highest on day 14 with levels much higher than
the therapeutic levels of EDX (Figure 48). The therapeutic levels were maintained in the
mammary glands treated with MSG until day 28. The lower levels of EDX on day 7
suggest a time dependent conversion of 4HT to EDX. Previous studies with 4HT shows
no enzymatic conversion which might be due to faster diffusion of 4HT out of the
mammary glands. Another possibility is the recirculation EDX from the circulation back
into the mammary glands. Further studies needs to be conducted to validate our findings
and also to test other possibilities like the role of enzyme induction associated with
SERM’s. 179
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Figure 47: Mammary gland concentration of 4HT treated with MSG and free 4HT on 7,
14 and 28 days. Data is Mean ± SD, n=3.
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Figure 48: Mammary gland concentration of EDX treated with MSG on 7, 14 and 28
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free 4HT.
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3.3.5 Time dependent lymph node retention study
To test the role of regional lymph nodes on the transport of formulations from the breast,
we determined the levels of 4HT at the regional lymph nodes at days 7, 14 and 28. As
reported in the previous chapter, microsphere drained through the regional lymph nodes
and was retained for 14 days (Figure 50). The lymph node levels of 4HT in MSG were 30
and 5-fold higher compared to free 4HT at days 7 and 14 respectively. EDX was present
at very low levels in the regional lymph nodes at day 7 in mammary glands treated with
MSG (Figure 50). According to previous studies, particle size plays a major role in
targeting distinct subsets of immune cells and occupies distinct areas of the lymph nodes.
Smaller particles (<200nm) are found to be associated with macrophages and larger
particles (>200 µm) are transported to the lymph nodes by dendritic cells.203, 204

Studies205, 206 have reported the improved retention of microparticles >1µm in the lymph
node upon oral and subcutaneous administration of microspheres. In a more recent study,
microparticles of different particle sizes were injected subcutaneously into the breast of
healthy rabbits to characterize lymphatic transport and also to assess the location of the
particles in the lymph node relative to the malignant cells 155. Results showed that 1µm
particles were 20 times more retained compared to 100nm nanospheres showing the
advantage of micrometric particles for lymph node targeted chemotherapy. This is possibly
due to a “washout phenomenon” of the nanoparticles by the efferent lymphatic system
where in the particles travel freely to the nodes and then exit from the nodes within the first
few hours after injection.
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Figure 50: Lymph node concentration of 4HT and EDX in rats treated with MSG on 7,
14 and 28 days. 4HT was undetectable at 28 days. EDX was undetectable after 7 days.
Data is Mean ± SD, n=3.
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3.4. CONCLUSIONS
4HT loaded PLGA MS with particle size 9.63 ± 1.49 µm and encapsulation and loading
efficiencies 92.46 ± 2.59 % and 10.46 ± 0.38 % respectively were prepared. Optimal drug
polymer ratio for PLGA microspheres and thermogel was found to be 1:10 % w/w. In vitro
release study showed sustained release of 4HT from MSG for 1 month. Pharmacokinetic
studies showed that MSG sustained therapeutic levels of 4HT and EDX in the mammary
glands and plasma for 28 and 14 days respectively. MSG formulation resulted in transport
of 4HT to the regional lymph nodes and was retained for 2 weeks. In vivo biodistribution
study showed minimal systemic distribution of 4HT and EDX with MSG compared to free
4HT. Taken together, this study demonstrates the feasibility of long-acting intraductal
formulations of 4HT that can sustain therapeutic levels in the mammary glands for ~1
month.
A summary of the findings from this chapter is depicted below.

Figure 51: Summary of findings from this chapter
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4. SUMMARY
The main goal of this dissertation was to demonstrate the feasibility of long-acting
intraductal delivery system for the breast. In the first study, PS particles of 1 µm were
retained for 3 days compared to the free dye which retained only few hours. PS particles
of 100nm and 500nm were retained only for 2 days. PLGA formulations with particle
size ~10µm (microspheres) and in situ forming gel systems showed retention of 4 days.
Free dye and nanoparticles (200-500 nm) diffused out of the ducts in 2- 4 hours and 24 36 hours respectively. The microspheres and in situ gel formulations showed reduced
systemic biodistribution. The whole mount images confirmed retention of the formulation
and distribution of formulation in the ducts. The microspheres and nanoparticles also
retained in the regional lymph nodes for 24 and 48 hours respectively. Based on these
findings, tamoxifen loaded PLGA microspheres and in situ gel formulations were
developed. PLGA microspheres and in situ gel retained tamoxifen in the mammary
glands for 14 days compared to free tamoxifen and PLGA nanoparticles, which was
retained for 3 and 6 days respectively. Also, 4-hydroxytamoxifen, a major metabolite of
tamoxifen was formed in the in the mammary glands treated with microspheres and in
situ gel. The systemic biodistribution study showed reduced systemic exposure with
microspheres and in situ gel. The TMX loaded PLGA nanoparticles and microspheres
were retained in the regional lymph nodes for 2 and 14 days respectively.
Based on these findings, the next objective focused on developing intraductal
formulations of 4HT, a potent metabolite of TMX. Further, the goal was to prolong drug
retention for 1 month. PLGA microspheres were combined with thermogel to achieve this
objective. The microsphere in gel formulation sustained 4-hydroxytamoxifen release 1
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month. Time dependent breast distribution study showed that therapeutic levels of 4hydroxytamoxifen was maintained for ~1 month using this formulation. On the other
hand, free 4-hydroxytamoxifen was retained in the breast only for 7 days. Endoxifen, a
major metabolite of 4-hydroxytamoxifen, was formed in the breast and the therapeutic
levels were maintained for 28 days in the breast. Pharmacokinetic studies showed that 4hydroxytamoxifen and endoxifen maintained therapeutic levels in the plasma for 14 days,
while free 4-hydroxytamoxifen showed no detectable levels of 4-hydroxytamoxifen and
endoxifen after 7 and 9 days respectively. Taken together, the findings from this
dissertation demonstrated the feasibility of developing long acting intraductal delivery
systems for prevention and treatment of breast cancer.
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5. FUTURE PROSPECTS
The findings from this dissertation can be used to guide future formulation design and
development of long-acting intraductal delivery systems. The future studies should focus
on:
•

Developing other formulation approaches such as drug-polymer conjugates and
combinatorial approaches with microspheres and/or in-situ gels to further sustain
drug release and prolong the drug levels in the breast for > 1 month

•

Mechanistic studies to understand the transport kinetics and pathways from the
breast to lymph nodes

•

Efficacy studies using suitable animal models including metastatic breast cancer
models.

•

Study the pharmacokinetics of long-acting formulations in a clinically translatable
animal model such as pig

•

Conduct long-term preclinical safety studies in animals

•

Develop and test intraductal formulations for macromolecules (biologics) and test
the retention in mammary glands
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